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Summary 
Excitation and inhibition in human cortex can be measured by transcranial 
magnetic stimulation (TMS) combined with electromyography (EMG) and 
electroencephalography (EEG) by way of specific markers of TMS-evoked 
muscle and brain responses. It has been shown that this capacity can be strongly 
enhanced by combining TMS-EMG/EEG with central nervous system (CNS) 
active drugs. Early studies have systematically investigated the role of a wide 
variety of CNS active drugs on motor evoked potentials (MEPs) and this 
knowledge is now partially applied to clinical settings. However, pharmacological 
alteration of TMS evoked EEG potentials (TEPs), which can provide direct 
information on cortical excitability and connectivity, has not been systematically 
elucidated yet. Here, we complement previous findings by using pharmaco-TMS-
EEG/EMG approaches to explore the physiological signatures of TEPs. In 
Experiment 1, we studied the effects of the experimental compound S44819, a 
selective α5-GABAAR antagonist, on TEPs and MEPs in 18 healthy young adults 
in a phase I study. In experiment 2, we investigated the role of three anti-epileptic 
drugs (carbamazepine, brivaracetam and tiagabine) on TEPs and MEPs in 15 
healthy male adults. 100 mg S44819 enhanced cortical excitability, as denoted 
by reduction of the amplitude of the N45 TEP component, as well as decrease of 
the motor threshold; carbamazepine decreased the amplitude of the P25 and 
P180 TEP components and increased motor threshold; brivaracetam decreased 
the N100 TEP amplitude and increased MEP threshold; tiagabine had no effect 
on TEPs and/or MEPs. Results of experiment 1 demonstrated for the first time 
effects of S44819 in the human cortex, that are relevant as S44819 showed 
potential to improve plasticity and learning in animal models of cerebral stroke. 
These findings led to further development of S44819 in a clinical phase II study 
to test its efficacy in enhancing recovery of function in stroke patients. Results of 
experiment 2 confirmed and extended previous findings that the P25 TEP 
component reflects axonal excitability of the corticospinal system, the N100 
potential in the non-stimulated hemisphere propagated activity mediated by 
inhibition of presynaptic neurotransmitter release, and the P180 late activity 
dependent on voltage-gated sodium channels (VGSCs). We believe that these 
updated pharmacological characterization of TEPs will prove useful for the 
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understanding of normal and dysfunctional cortical excitability and inhibition of 
the human brain. 
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General Introduction 
Transcranial magnetic stimulation (TMS) is a powerful non-invasive brain 
stimulation technique which is widely used in systems neurophysiology, cognitive 
and clinical neuroscience, and neuropsychiatry (Barker, Jalinous, & Freeston, 
1985; Hallett, 2000; Walsh & Cowey, 2000). The rationale behind how TMS is 
able to induce changes in the electrical activity of the brain is based on Faraday’s 
principle of induction of an electric current by a fluctuating magnetic field 
(Faraday, 1846). A simple TMS machine consists of a stimulating coil, a bank of 
energy-storing capacitors, and low resistance cables. When the TMS machine 
generates a single pulse, the stored energy in the capacitors is released and an 
intense time-varying current pulse runs through the coil, which in turns produces 
a brief intense magnetic field (Barker et al., 1985; Jalinous, 1991). This magnetic 
field induces an intracranial current without significant attenuation by the skull 
and/or dura. This can result in depolarization of cell membranes and initiation of 
action potentials, and thus change the neuronal firing pattern and organization 
which can in the short term excite or inhibit specific brain areas (Hallett, 2000; 
O'Shea & Walsh, 2007). Central motor pathways can easily be targeted by TMS 
and cause muscle responses on the contralateral side of the body (Muellbacher 
et al., 2002), while excitation of sensory systems is more challenging to attain. It 
is well-established that various stimulation settings (e.g., single pulse, paired-
pulse and repetitive TMS) are able to produce dissimilar effects on cortical 
excitability and inhibition, either transiently or lastingly (RMMF Chen et al., 1997; 
Fitzgerald, Fountain, & Daskalakis, 2006; Pascual-Leone et al., 1998). The 
alteration of specific motor functions, as a consequence of TMS over primary 
motor cortex (M1), has traditionally been quantified by the consecutive or 
concurrent recording of neurophysiological responses through surface 
electromyography (EMG) from a muscle. The conventional readouts of single 
pulse TMS over M1 are resting motor threshold (RMT) and motor evoked 
potential (MEP) size, which are recorded by EMG. RMT is typically defined as the 
minimal stimulator intensity that is required to produce a small reliable MEP in a 
resting muscle (usually a hand muscle). It has been hypothesized that the RMT 
represents the excitability of a central core of neurons which are excited by TMS, 
and in response transmit action potentials (Hallett, 2000). The magnitude of an 
MEP is usually measured as either the average response to a series of pulses 
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applied at a steady stimulator intensity or as the growth in MEP size as a function 
of stimulus intensity (referred to as an MEP input-output curve) (E. M. 
Wassermann, 1998). It has been thought that the activity of neurons other than 
those in the hypothesized ‘core region’  contribute to the measured MEP 
amplitude, and  these neurons have been shown to have a higher threshold for 
activation, probably due to their location (more remote from the center of 
stimulation) or nature (less excitable) (Hallett, 2000). However, the basic 
physiology behind measures of motor cortical excitability was less well 
understood until 1996, when Ziemann et al. laid the basis for pharmaco-TMS 
studies (Ziemann, Lonnecker, Steinhoff, & Paulus, 1996). The basic concept 
behind these studies is that CNS-active drugs, with distinct mechanisms of action, 
can be used to characterize TMS measures of motor cortical excitability since 
various drugs would produce unalike effects on MEP patterns. In pharmaco-TMS, 
a single dose of a drug of interest is given and changes in motor excitability, 
measured by TMS, are compared with a baseline and/or placebo condition. Many 
studies have systematically investigated the pharmacological characterization of 
MEPs. For instance, several studies showed that RMT can be influenced by 
drugs that affect voltage-gated ion channels, like carbamazepine and lamotrigine 
which acts as voltage-gated sodium channel (VGSC) blockers (for review see 
(Ziemann et al., 2015)). Whereas modulation of the major CNS neurotransmitter 
systems, like the gamma-aminobutyric acid (GABA) system, either had no effect, 
or inconsistent effects, on the motor threshold (for review see (Paulus et al., 
2008)). Therefore, these results support the hypothesis that RMT represents 
axon membrane excitability. Results from pharmaco-TMS studies also suggest 
that MEP size reflects the transsynaptic excitation of corticospinal neurons, as 
some of neurotransmitters and neuromodulators (for example GABA, Glutamate, 
Dopamine, and Norepinephrine) have been shown to modulate MEP size and 
MEP input-output curve (mostly at the high-amplitude MEP range) (Ziemann et 
al., 2015) while voltage-gated ion channels had inconsistent or no effects on MEP 
size (for review see (Paulus et al., 2008)). Pharmaco-TMS studies also reported 
in several cases that the change in MEP size happens without changes in RMT, 
this also supports the initial hypothesis that the mechanisms underlying RMT and 
MEPs are different (E. Wassermann et al., 2008). 
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Pharmaco-TMS has not been limited to single-pulse stimulation protocols but has 
also been utilized with other protocols, such as paired-pulse techniques. In 
paired-pulse stimulation a sub-threshold conditioning stimulus (S1) followed by a 
supra-threshold test stimulus (S2) and the S1 induces a short-term modulation of 
the amplitude of the MEP produced by the S2. Several studies showed that the 
MEP amplitudes are inhibited at inter-stimulus intervals (ISIs) of 1–5 ms and are 
facilitated at ISIs of 7–20 ms and these phenomena are commonly referred to as 
short-interval intracortical inhibition (SICI) and intracortical facilitation (ICF) 
(Kujirai et al., 1993; Sanger, Garg, & Chen, 2001; Ziemann, Corwell, & Cohen, 
1998; Ziemann, Rothwell, & Ridding, 1996). It has been shown that positive 
modulators of GABAARs, such as benzodiazepines, increase SICI (for review 
see (Ziemann et al., 2015)), thus suggesting that intracortical inhibition may in 
principal be mediated by GABAARs. On the other hand, the physiological 
signature of ICF is less evident than SICI and one suggestion is that ICF might 
reflect excitability of an excitatory motor cortical pathway separate from the SICI 
circuitry (Ziemann et al., 2015; ULF Ziemann et al., 1996). It is worth mentioning 
that although pharmaco-TMS has contributed significantly to a better 
understanding of cortical excitability in healthy brains and in those with brain 
disorders (Robert Chen et al., 2008) a relevant limitation of this technique is that 
the TMS effects are measured indirectly from a muscle and not the brain, 
meaning that spinal and cortical mechanisms that may underlie the neural 
responses to TMS cannot be fully disentangled. Another limitation is that EMG 
measures are limited to motor cortex as only TMS of M1 produces muscle 
twitches (or in the other word MEPs) and so the impact of TMS on non-motor 
regions (i.e. prefrontal and occipital cortex) cannot be studied.  
More recent work has sought to combine TMS with several other 
electrophysiological and neuroimaging techniques, such that neural processes 
outside the motor system can be directly examined. For example, investigation 
of the prefrontal and occipital cortex can be achieved by the concurrent recording 
of neurophysiological responses through scalp electroencephalography (EEG) 
following TMS pulses (Daskalakis et al., 2008; Farzan et al., 2009). EEG traces 
in response to TMS pulses reveal the temporal and spatial summation of the 
TMS-induced excitatory and inhibitory postsynaptic potentials (Kirschstein & 
Köhling, 2009). A series of studies have shown that TMS over cortex evokes a 
10 
 
sequence of positive and negative deflections within the first few 100 ms after 
stimulation onset. In particular, TMS over M1 has been shown to generate highly 
reproducible TMS-evoked potentials (TEPs) which are typically labeled according 
to their polarity and latency: P25, N45, P70, N100 and P180 (P: positive; N: 
negative) (Bonato, Miniussi, & Rossini, 2006; Casarotto et al., 2010). However, 
the neurophysiological mechanisms that underlie TEPs are not well-known. 
Pharmaco-TMS-EEG was thus recently developed to identify TMS-EEG markers 
of cortico-cortical excitability and effective connectivity in the healthy brain 
(Premoli, Castellanos, et al., 2014; Premoli, Rivolta, et al., 2014). This method 
has been utilized to characterize the underlying physiology of TMS-evoked brain 
responses by using CNS-active drugs with specific mechanisms of action, as well 
as to interrogate newly developed CNS-active drugs with respect to their 
modulation of specific TEP components. In these studies, changes in TEPs after 
application of a single dose of the study drug are compared to a baseline and/or 
placebo condition in a randomized, placebo-controlled, double-blind crossover 
design. Recent pharmaco-TMS-EEG studies have systematically demonstrated 
effects of several GABAergic drugs on TEPs. For instance, classical 
benzodiazepines (alprazolam and diazepam), which are positive modulators at 
the GABAA receptor, increase the N45 potential amplitude, and decrease the 
N100. Conversely, baclofen, which acts as a specific agonist at the GABAB 
receptor, raised the N100 potential amplitude and had no effect on the N45. 
Taken together, these results suggested that the N100 is negatively related to 
GABAA but positively to GABAB receptor-mediated neurotransmission (Premoli, 
Castellanos, et al., 2014; Premoli, Rivolta, et al., 2014). However, in order to gain 
a more comprehensive overview of how TEPs could be utilized as new markers 
of excitation and inhibition in the human brain, the effect of CNS active drugs with 
other modes of action on TEPs needed to be investigated. Such measures are 
useful in understanding the changes in brain physiology observed in physiological 
processes such as plasticity, and pathological processes in brain disorders. 
Several groups have already started preliminary clinical research in this direction; 
for example, TMS-EEG in epilepsy patients has shown that late motor cortex TEP 
components are abnormal in comparison to those in healthy controls (Del Felice, 
Fiaschi, Bongiovanni, Savazzi, & Manganotti, 2011; Julkunen et al., 2013; Shafi 
et al., 2015; Valentin et al., 2008). 
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Aims and scopes of this dissertation 
 
In order to depict the pharmaco-physiological profile of TEPs and to explicate the 
mode of action of a newly industrialized CNS-active drug, we used the pharmaco-
TMS-EEG/EMG approaches described in the introduction.  
 
First, we tested the effects of a single oral dose of S44819, a novel competitive 
selective antagonist of α5-GABAAR, on cortical excitability in 18 male participants 
in a randomized, double-blinded, placebo-controlled, crossover phase I study (1st 
study, Appendix 1).  
 
Second, we studied the pharmacological influences of three anti-epileptic drugs 
(AEDs) with well-defined modes of action including carbamazepine, a voltage-
gated sodium channel (VGSC) blocker, brivaracetam, a ligand to the presynaptic 
vesicle protein VSA2, and tiagabine, a selective GABA reuptake inhibitor, on 
cortical excitability in a placebo-controlled crossover study in 15 male participants 
(2nd study, Appendix 2). 
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Summary of scientific findings 
 
Study 1: ‘Effects of the Selective alpha5-­‐‑GABAAR Antagonist S44819 on 
Excitability in the Human Brain: A TMS-­‐‑EMG and TMS-­‐‑EEG Phase I Study’. 
 
We showed that the 100 mg S44819 reached human cortex and significantly 
increased the corticocortical and corticospinal excitability as indexed by a 
decrease in motor threshold measured by TMS–EMG and a decrease of the 
amplitude of the N45 component of the TMS–EEG responses. Also, we indicated 
that the peak serum concentration of 100 mg S44819 correlated with the 
decrease in N45 amplitude.  
 
Study 2: ‘Effects of antiepileptic drugs on cortical excitability in humans. A TMS-
EMG and TMS-EEG study’. 
 
Using TMS-EEG/EMG and three anti-epileptic drugs with specific modes of 
action, we showed that carbamazepine increased both motor and MEP threshold, 
brivaracetam only increased MEP threshold and tiagabine didn’t alter motor or 
MEP threshold. We then showed that carbamazepine suppressed the amplitudes 
of the P25 and P180 TEP components, with and without adjusting stimulus 
intensity by the change in motor threshold in the post-drug measurements, while 
brivaracetam decreased the N100 over the contralateral sensorimotor cortex. For 
tiagabine, no significant TEP modulation could be established. Drug-induced 
changes in spontaneous oscillatory spectral power in the resting-state EEG and 
pre-TMS periods revealed that tiagabine caused a strong broadband increase in 
spontaneous oscillatory power in all frequency bands (delta, theta, alpha, and 
beta) which was most pronounced in the delta and theta bands (7-8 fold).  
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Overall conclusion and outlook 
The scope of this dissertation was first to deepen the understanding of the 
physiological processes underlying TEPs by combining TMS-EEG with CNS 
active drugs with specific modes of action (GABAergic system, voltage-gated ion 
channels etc.), and second to use TMS-EEG as a non-invasive method to 
characterize the mode of action of a newly developed CNS active drug (S44819).  
In this thesis, by employing TMS-EEG/EMG, we could show convincing evidence 
that a sufficient concentration of S44819 reached human cortex and 
subsequently increased corticospinal and cortical excitability. Noticeably, 
pharmacological reduction of α5-GABAAR-mediated inhibitory tone could be 
important in several neurological pathologies including stroke. For instance, 
ischemic stroke triggers a hypo-excitability in the peri-infarct motor cortex mainly 
due to over-activation of α5-GABAA receptors (Clarkson, Huang, MacIsaac, 
Mody, & Carmichael, 2010). Therefore, counteracting exaggerated α5-GABAAR-
mediated inhibition could allow faster functional recovery after stroke (Clarkson 
et al., 2010; Hermann & Chopp, 2012).  
Moreover, we extended and confirmed previous findings by identifying the TEP 
signatures of voltage-gated ion channels and GABAergic system activity in the 
human brain, by using three well-known AEDs. Although AEDs provide 
satisfactory control of seizures for most patients with epilepsy, a significant 
fraction of patients (around one-third) with newly diagnosed epilepsy do not 
achieve freedom from seizures with a modest dose of a single AED (Cascino, 
2008; Kwan & Brodie, 2000). It should, however, be mentioned that the 
investigation of AED-induced modulation of cortical excitation in epileptic patients 
is complex due to the high number of specific syndromes and the remarkable 
diversity of molecular targets of AEDs. Hence, the pharmaco-TMS-EEG work 
presented in this dissertation may give new insights into the effects of AEDs on 
cortical functioning.  
In the following paragraphs, the updated ‘big-picture’ of the neurophysiological 
underpinnings of primary motor cortex TEPs will be discussed. 
P25: The early TEP components of motor cortex have been shown to be putative 
markers of excitation of the corticospinal system, since following M1 stimulation, 
motor cortical regions respond between 3-28 ms after the TMS pulse (Ilmoniemi 
et al., 1997; Komssi et al., 2002). Also, other studies showed that rTMS and tDCS 
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(methods that modulate cortical excitability) significantly alter only the early 
components of motor cortex (Esser et al., 2006; Veniero, Bortoletto, & Miniussi, 
2012). Our results confirm this notion by demonstrating that carbamazepine (as 
a classic excitability-lowering drug) suppresses the P25 component at the site of 
stimulation (Darmani et al., under revision). Altogether these findings support the 
feasibility of measuring cortical excitability after pharmacological interventions 
and suggest that the P25 component is a marker of axonal excitability of the 
corticospinal system.  
N45: We showed that after application of 100 mg S44819, only the N45 TEP 
component was suppressed, whereas other components remained unaffected 
(Darmani et al., 2016). These results complement previous findings which 
showed that benzodiazepines and zolpidem increase the amplitude of the N45 
component (Premoli, Castellanos, et al., 2014; Premoli, Rivolta, et al., 2014) and 
therefore N45 is likely mediated by neurotransmission through GABAA receptors. 
N100: Our TMS-EEG experiments in combination with brivaracetam updated 
previous findings (Premoli, Castellanos, et al., 2014; Premoli, Rivolta, et al., 2014) 
regarding the N100 component, and suggest that drugs with inhibition of 
presynaptic excitatory transmitter release (such as BRV) decrease the activity of 
the N100 in the non-stimulated hemisphere (Darmani et al., under revision). 
Although, the exact underlying physiology of N100 reduction in the non-
stimulated hemisphere requires further investigations, but may indicate a 
reduction in overall signal propagation and long-range connectivity in the cortex. 
P180: Previous results of a TMS-EEG study on the effects of AEDs on TEPs in 
healthy subjects showed a decrease in the P180 potential by lamotrigine (another 
classical VGSC blocker) (Premoli, Costantini, Rivolta, Biondi, & Richardson, 
2017). The suppression of the P180 component under carbamazepine in our 
experiments, with and without adjusting stimulus intensity to the change in motor 
threshold, highlighted the sensitivity of the late TEPs to VGSC blockage (Darmani 
et al., under revision). Thus, P180 might reflect VGSC activity. 
It should be mentioned that we used a neuronavigation system to make sure that 
TMS positioning over each subject’s head is consistent across sessions. This is 
methodologically crucial especially if one wants to replicate/extend the present 
findings to cortical areas outside of the motor strip (Casarotto et al., 2010; 
Lioumis, Kicic, Savolainen, Makela, & Kahkonen, 2009). 
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Although pharmaco-TMS-EEG is potentially a very useful tool to investigate the 
intrinsic and functional properties of brain systems non-invasively, several limiting 
and confounding factors should be considered when using this technique, in order 
to broaden its applications and increase the reliability of results across studies. 
In the following, some of these issues will be discussed briefly: 
The use of TMS-EEG has been mainly limited to the cerebral cortex as the EEG 
signals cannot reflect deeper brain activity emerging from subcortical structures. 
Therefore, in order to reliably localize the cortical areas that play a part in the 
pharmacological modulation of TEPs, cortical source modeling of TEPs would be 
needed in future studies. One other possibility to overcome this limitation is to 
combine TMS-EEG with other techniques such as fMRI to investigate causal 
interactions between cortical as well as subcortical areas at a better spatial 
resolution.  
Recent studies, including ours, show that drug effects on TEPs may depend on 
the stimulation intensity, since drugs may modulate motor and MEP thresholds 
(Darmani et al., under revision; Premoli et al., 2017). Therefore, it would be 
important to consider these threshold changes and adjust stimulation intensities 
in individual subjects in post-drug measurements accordingly.  
It has also been shown that instantaneous brain state may have an impact on the 
reliability of TEP measurements (Bortoletto, Veniero, Thut, & Miniussi, 2015; Keil 
et al., 2013; Rosanova et al., 2009). In addition, since some drugs influence 
spontaneous brain oscillations dramatically, the reliable detection of TEPs in 
post-drug measurements may consequently be impeded as a result of drug-
induced altered brain states. 
A final issue are the methodological problems in dealing with TMS related 
artifacts. Studies have shown that TMS at effective stimulus intensities may 
cause significant unwanted auditory and somatosensory pathway co-activation 
due to a loud click and a tapping sensation as a result of the TMS pulse.  These 
auditory-evoked potentials (AEP) and sensory-evoked potentials (SEP) are 
superimposed over the true TEPs and difficult to disentangle from direct 
transcranial cortical activation (Conde et al., 2018; Conde et al., 2012; Rogasch 
et al., 2014). Some solutions to these problems have been suggested by (Farzan 
et al., 2016; Herring, Thut, Jensen, & Bergmann, 2015) and could potentially be 
used in future studies to reduce the effects of AEPs and SEPs. However, a more 
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secure solution is realistic sham stimulation to account for the contamination of 
drug effects on TEPs by drug-induced changes in AEPs and SEPs.  
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Effects of the Selective 5-GABAAR Antagonist S44819 on
Excitability in the Human Brain: A TMS–EMG and TMS–EEG
Phase I Study
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XPaolo Belardinelli,1Matthias Schwab,2,4,5 and XUlf Ziemann1
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Alpha-5 gamma-aminobutyric acid typeA receptors (5-GABAARs) are located extrasynaptically, regulateneuronal excitability through
tonic inhibition, and are fundamentally important for processes such as plasticity and learning. For example, pharmacological blockade
of 5-GABAAR in mice with ischemic stroke improved recovery of function by normalizing exaggerated perilesional 5-GABAAR-
dependent tonic inhibition. S44819 is a novel competitive selective antagonist of the 5-GABAAR at the GABA-binding site. Pharmaco-
logicalmodulation of5-GABAAR-mediated tonic inhibitionhas never been investigated in the humanbrain.Here,weused transcranial
magnetic stimulation (TMS) to test the effects of a single oral dose of 50 and 100 mg of S44819 on electromyographic (EMG) and
electroencephalographic (EEG) measures of cortical excitability in 18 healthy young adults in a randomized, double-blinded, placebo-
controlled, crossover phase I study. A dose of 100mg, but not 50mg, of S44819 decreased activemotor threshold, the intensity needed to
produce amotor evoked potential of 0.5mV, and the amplitude of the N45, a GABAAergic component of the TMS-evoked EEG response.
The peak serum concentration of 100 mg S44819 correlated directly with the decrease in N45 amplitude. Short-interval intracortical
inhibition, a TMS–EMGmeasure of synaptic GABAAergic inhibition, and other components of the TMS-evoked EEG response remained
unaffected. These findings provide first time evidence that the specific5-GABAAR antagonist S44819 reached human cortex to impose
an increase in cortical excitability. These data warrant further development of S44819 in a human clinical trial to test its efficacy in
enhancing recovery of function after ischemic stroke.
Key words: 5-GABAAR; excitability; human cortex; motor evoked potential; TMS–EEG; tonic inhibition
Introduction
The 5-subunit containing gamma-aminobutyric acid type A
receptors (5-GABAARs) predominate in the hippocampus, but
are also expressed in the neocortex (Quirk et al., 1996; Mo¨hler et
al., 2002). They are located extrasynaptically at the base of the
spines and on the adjacent shafts of pyramidal cell dendrites and
are therefore in a privileged position tomodulate excitatory input
to pyramidal cells through tonic inhibition (Bru¨nig et al., 2002;
Received May 26, 2016; revised Sept. 18, 2016; accepted Oct. 17, 2016.
Author contributions: G.M.B., K.D., F.M.-D.,M.S., and U.Z. designed research; G.D., C.M.Z., and G.M.B. performed
research; G.D., F.M.-D., P.B., and U.Z. analyzed data; G.D., P.B., and U.Z. wrote the paper.
This work was supported by the Institut de Recherches Internationales Servier. M.S. was supported
by Robert Bosch Stiftung, Stuttgart, Germany. We thank Drs. Moerike, Gleiter, and Igel for local study
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Significance Statement
Theextrasynaptic-5gamma-aminobutyricacidtypeAreceptor(5-GABAAR)regulatesneuronalexcitability throughtonic inhibition
inthemammalianbrain.Tonic inhibitionis important formanyfundamentalprocessessuchasplasticityandlearning.Pharmacological
modulation of 5-GABAAR-mediated tonic inhibition has never been investigated in the human brain. This study demonstrates that
S44819, a selective5-GABAARantagonist, increases cortical excitability inhealthyhumansubjects, as indicatedby specificmarkers of
transcranial magnetic stimulation-inducedmuscle and brain responses measured by electromyography and electroencephalography.
Our findings imply that tonic inhibition in human cortex can bemodified effectively and that this modification can be quantified with
noninvasive brain stimulationmethods. The actions of S44819may be suitable to improve plasticity and learning.
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Farrant and Nusser, 2005; Mo¨hler, 2006). Accordingly, increas-
ing tonic inhibition shifts the input–output relationship of single
cells to the right; that is, the probability of action potential gen-
eration to a given excitatory input decreases (Mitchell and Silver,
2003). Animal models demonstrated that specific pharmacolog-
ical blockade, point mutations, or null mutants of 5-GABAARs
enhance learning processes (Crestani et al., 2002;Maubach, 2003;
Martin et al., 2010), whereas activation of 5-GABAARs reduces
synaptic plasticity (Martin et al., 2010).
Acute ischemic stroke inmice and rats causes hypoexcitability
in the peri-infarct cortex through increased tonic inhibition by
overexpression and overactivation of 5-GABAARs (Clarkson et
al., 2010; Schmidt et al., 2012). Pharmacological blockade or ge-
netic lowering of the expression of 5-GABAARs enhances func-
tional recovery after stroke in mice (Clarkson et al., 2010).
Although increased tonic inhibition may be neuroprotective in
the acute phase after ischemic stroke, counteracting excessive
5-GABAAR-mediated tonic inhibition in the subacute phase of
stroke may allow a greater and/or more rapid recovery in stroke
patients (Carmichael, 2012).
S44819 is a novel potent, competitive,and selective antagonist
at the GABA-binding site of the 5-GABAAR tested in vitro
(Etherington et al., 2016). It is as of yet unclear to what extent a
single oral dose of S44819 is capable of reducing inhibition me-
diated by 5-GABAARs and thus increasing excitability in the
human brain. Here, transcranial magnetic stimulation (TMS)
was used in young healthy adults to obtain electromyographic
(EMG) and electroencephalographic (EEG) markers of cortical
excitability. Motor threshold, intensity needed to elicit a motor
evoked potential (MEP) of a given amplitude, and short-interval
intracortical inhibition (SICI) were obtained as classical TMS–
EMG markers. Motor threshold represents axon membrane ex-
citability, while SICI reflects synaptic GABAAergic inhibition of
corticospinal neurons (for review (Ziemann et al., 2015)). The
N45 component of the TMS-evoked EEG potential (TEP) in-
volves GABAAergic activity, as benzodiazepines, i.e., allosteric
positive modulators at GABAARs increase this potential (Pre-
moli et al., 2014a; Premoli et al., 2014b). We hypothesized that
S44819 would decrease the motor threshold and the intensity
needed to elicit an MEP of a given amplitude, signifying a left-
ward shift in the input-output relationship of corticospinal neu-
rons to TMS excitation, but would not affect SICI, a paired-pulse
TMS measure of synaptic (phasic) rather than extrasynaptic
(tonic) inhibition. Furthermore, we expected that S44819 would
decrease the N45 amplitude given its previously established
GABAAergic nature.
Materials andMethods
Participants
Eighteen healthy male volunteers (mean age  SD: 27.5  6.0 years;
range 21–43) participated in this study after having provided written
informed consent. All subjects were strongly right-handed according to
the Edinburgh handedness inventory (mean laterality index of handed-
ness SD: 87 9; range 75–100; Oldfield, 1971), free of medication and
any drug abuse (including alcohol and nicotine), andwithout any history
of neurological or psychiatric diseases. All subjects underwent the Trans-
cranial Magnetic Stimulation Adult Safety Screen (TASS; Keel et al.,
2001), followed by a physical examination and a diagnostic EEG to rule
out any contraindications against the TMS procedures of this study. At
screening, participants were included if the resting motor threshold
(RMT) was50% of maximum stimulator output (MSO) and the stim-
ulus intensity (SI) needed to elicit MEPs of, on average, 0.5 mV in peak-
to-peak amplitude was70%MSO. Blood alcohol test, drug screening,
and urinary cotinine test were performed on the day before each exper-
iment and participants had to have negative results in all tests to be
allowed to take part in the study. Experimental procedures conformed to
the Declaration of Helsinki and the Federal Institute for Drugs andMed-
ical Devices (Bundesinstitut fu¨r Arzneimittel undMedizinprodukte) and
the local ethics committee of the Medical Faculty of Eberhard-Karls-
University Tu¨bingen approved the study (EudraCT #2014-004681-13).
Experimental design
To evaluate whether the antagonistic action of S44819 on 5-GABAARs
detected in preclinical studies in vitro is relevant for the modulation of
the human primary motor cortex (M1) excitability, a randomized,
double-blinded, placebo-controlled, crossover study investigated the ef-
fects of a single oral dose of 50 and 100 mg of S44819 on TMS–EMG and
TMS–EEG measures of corticospinal and cortical excitability. Partici-
pants were assigned to one of the six possible sequences of treatment
(three subjects were allocated in each of the six sequences of treatment),
which all included three successive treatment periods during which pla-
cebo, 50 mg S44819 or 100 mg S44819 was administered. One week
separated each of the treatment periods to exclude the possibility of
carryover effects between treatment periods according to a S44819 serum
half-life of 7 h in human (Institut de Recherches Internationales
Servier, 2014). Drug dosages were chosen based on extrapolation of
pharmacokinetic (PK) results in animal models and doses presenting
satisfactory clinical safety in a first human phase I study of S44819 (In-
stitut de Recherches Internationales Servier, 2016). To ensure controlled
conditions for food and fluids for all participants, they were admitted to
our phase I unit on the evening of the day before each treatment period.
TMS measurements were performed on next morning starting either at
8:00 A.M. or 10:00 A.M. (always at the same time for a given participant).
TMS sessions always followed the same sequence and timing of investi-
gations (Fig. 1): baseline TMS–EMG and TMS–EEGmeasurements; first
PK blood sampling, oral study drug intake; waiting period of 150 min;
second PK blood sampling (at2 h after study drug intake); TMS–EEG
and TMS–EMG postdrug measurements; and further PK blood sam-
plings (at4 h,6 h,8 h after study drug intake). The timing of TMS
postdrug measurements was based on the PK data from a first human
phase I study estimating themaximum systemic levels of S44819 between
2.5 and 4 h after oral intake (Institut de Recherches Internationales
Servier, 2014).
Data recording
TMS. Participants were asked to sit on a comfortable reclining chair and
stay awake with eyes open. Monophasic TMS pulses were applied over
the hand area of the dominant (left) M1 using two Magstim 2002 mag-
netic stimulators connected to a figure-eight coil (outer diameter of each
wing, 70 mm) through a BiStimModule (Magstim). The coil was placed
tangentially on the scalp with the handle pointing backwards and 45°
away from the midline. This way, the direction of the TMS-induced
current in the brain was from lateral–posterior to medial–anterior, lead-
ing to largely transsynaptic excitation of corticospinal cells through hor-
izontal corticocortical connections (Di Lazzaro et al., 2008). The hand
representation of the left M1 was determined and marked with a pen on
the scalp as the coil position, where TMS at a marginally suprathreshold
stimulus intensity consistently resulted in largest MEPs in the right first
dorsal interosseus (FDI) muscle. MEPs were recorded by using surface
EMGwith Ag-AgCl cup electrodes in a belly–tendon arrangement. EMG
data were recorded by spike2 software (Cambridge Electronic Design),
the raw signal was amplified (Digitimer D360 8-channel amplifier),
band-pass filtered (20Hz to 2 kHz), and digitized at an A/D rate of 5 kHz
(CEDMicro 1401; Cambridge Electronic Design). Single-pulse TMSwas
used to determine RMT, active motor threshold (AMT), and stimulus
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intensity needed to elicit a motor evoked potential of 0.5 mV amplitude
(SI0.5mV). RMT was defined as the lowest stimulus intensity eliciting a
MEP of50 V in peak-to-peak amplitude in at least five of 10 succes-
sive trials (Groppa et al., 2012). AMT was determined in the slightly
voluntarily contracting FDImuscle (10% ofmaximum voluntary con-
traction monitored by audiovisual feedback of the EMG signal) as the
lowest stimulus intensity resulting in aMEP of100V in peak-to-peak
amplitude in at least five of 10 successive trials. SI0.5mVwas determined
as the stimulus intensity required for MEPs of, on average, 0.5 mV in
peak-to peak amplitude in the voluntarily relaxed FDI. SICIwas tested by
paired-pulse TMS. The SICI paradigm involved pairing of a conditioning
stimulus (CS) followed by a test stimulus (TS) at a short interstimulus
interval of 2.0 ms to avoid possible contamination by short-interval in-
tracortical facilitation (Peurala et al., 2008). A SICI intensity curve was
obtained with CS intensities ranging from 50% AMT to 120% AMT in
steps of 10% AMT (i.e., 8 different CS intensities) and TS intensity of
SI0.5mV. TS intensity was adjusted tomaintain a testMEP amplitude of,
on average, 0.5 mV in the postdrug SICI measurements. CS/TS and TS
alone conditions were repeated 10 times each in randomized order in a
block of 90 trials. The intertrial interval varied randomly between 4 and
8 s to limit anticipation of the next trial. SICI datasets from 5/18 subjects
had to be discarded from analysis because of incomplete voluntary relax-
ation of the FDI or too small test MEP amplitudes (200 V). Both
factors can lead to a nonspecific (drug-unrelated) reduction of SICI (Rid-
ding et al., 1995; Sanger et al., 2001).
EEG recordings. To evaluate TEPs, EEG was recorded parallel with the
EMG recordings. EEG signals were acquired through TMS-compatible
EEG equipment (BrainAmp DC; Brain Products) using a 64-channel
EEG cap (BrainCap-Fast’n Easy; Brain Products). FCz and AFz served as
the active reference and ground electrodes, respectively. To monitor eye
movement artifacts and blinks, two more electrodes were placed outside
of the outer canthus and over the right eye. Electrode impedances were
maintained at 5k throughout the experiment. EEG signals were re-
corded via BrainVision Recorder software version 1.20 (BrainProducts)
with a resolution of 0.5V/bit, a low-pass filter of 1 kHz, and a sampling
rate of 5 kHz. During the TMS–EEG recordings, white noise was applied
through ear phones to mask the TMS click and to avoid TMS-evoked
auditory potentials (Massimini et al., 2005; Casarotto et al., 2010). A total
of 130 TMS pulses were applied at baseline and 150min after drug intake
over the FDI hotspot of the left M1 at 100% RMT as determined at
baseline; that is, no adjustment of stimulus intensity was made in the
postdrug TMS–EEG measurements. Because there were no drug effects
onRMT (cf. Fig. 3), the observed drug effects onTEPs (see below) cannot
be accounted for by changes motor threshold. MEPs were monitored
visually during TMS–EEG recording. No or only miniature MEPs were
elicited. This ensured that the somatosensory afferent signals caused by
muscle twitcheswere absent and therefore did not contaminate the TEPs.
The intertrial interval varied randomly between 4 and 8 s to limit antic-
ipation of the next trial.
Data analyses
TMS–EMG analysis. EMG data were analyzed via Spike2 software (Cam-
bridge Electronic Design) and MATLAB (R2015a, RRID:SCR_000903;
The MathWorks). Peak-to-peak MEP amplitudes were calculated for
each trial and averaged per each condition. The SICI intensity curve was
obtained by calculating the ratio of mean conditionedMEP (eight differ-
ent CS intensities: 50%, 60%, 70%, 80%, 90%, 100%, 110%, and 120%
AMT) over mean test MEP (SI0.5mV). For assessment of possible drug-
induced changes in RMT, AMT, SI0.5mV, and test-MEP, two-way
repeated measures ANOVA (rmANOVA) was used, with the main
within-subject effects of time (two levels: baseline and postdrug) and
drug condition (three levels: placebo, 50 mg S44819, and 100 mg
S44819). For SICI, a three-way rmANOVAwith the main within-subject
effects of time, drug condition, and CS intensity (8 levels: 50–120%
AMT) was run. Order effects were assessed by substituting the main
effect of drug condition by period (three levels: period 1, period 2, and
period 3). In case of significant interactions between time and drug con-
dition (or period), post hoc tests were applied to compare effects between
the single drug conditions. Differences were considered significant
whenever p 0.05.
TMS–EEG analysis. EEG data were processed offline using BrainVi-
sion Analyzer software (version 2.0, RRID:SCR_002356; BrainProducts)
and the Fieldtrip open source toolbox (www.ru.nl/fcdonders/fieldtrip/,
RRID:SCR_004849) running in MATLAB (R2015a; The MathWorks).
The EEG raw data were re-referenced to linked mastoid electrodes and
downsampled to 1 kHz. All trials were inspected visually to remove
artifact-contaminated trials caused by movements, blinks, or TMS-
related muscle artifacts. Artifact-free trials were segmented from 500
ms to 500 ms relative to the TMS pulse and then, to remove the electro-
magnetic TMS artifact, a linear interpolation was applied from10 ms
to 10ms around eachTMSpulse (Thut et al., 2011; Premoli et al., 2014b).
Next, epochs were baseline corrected by subtracting the mean amplitude
of the channel signal during an interval between500 ms and100 ms
before the TMS pulse. A digital band-pass filter was then applied (2–80
Hz). Further, a notch filterwith a stop band centered at 50Hzwas applied
for noise-line correction. Independent component analysis was then
used to remove components reflecting TMS-inducedmuscle activity and
TMS artifacts (within the first 50 ms after the TMS pulse) from TEPs
based on each participant’s data (Rogasch and Fitzgerald, 2013; Rogasch
et al., 2014). Averages at each recording channel were calculated across
the retained trials (mean  SEM, 98  4, range 74–118), and finally
grand averaged TEPswere computed by averaging per condition (2 levels
of time, 3 drug conditions) across all participants. A 45Hz low-pass filter
was applied to smooth the TEP components with latency200 ms. Five
TEP components were considered (P25, N45, P70, N100, and P180) due
to their consistent reproducibility upon M1 stimulation as reported in
several other studies (Bonato et al., 2006; Lioumis et al., 2009; Ferreri et
al., 2011; Premoli et al., 2014b). For their quantitative analysis, five time
windows of interest (TOIs)were defined, based on the grand averageTEP
components: P25 (15–35 ms), N45 (38–60 ms), P70 (63–82 ms), N100
(85–119 ms), and P180 (156–230 ms; Fig. 2; Premoli et al., 2014a; Pre-
moli et al., 2014b). These TOIs were adjusted individually to take into
account interindividual variability of TEP peak latencies and peak am-
plitudes of the TEP components were determined for each participant,
Figure 1. Timeline of experiments. TMS–EMG and TMS–EEG measures were obtained immediately before and 150 min after study drug intake (100 mg S44819, 50 mg S44819, or placebo).
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time point, and drug condition. To correct for multiple comparisons
(i.e., electrodes, time points within TOIs), a cluster-based permutation
analysis (Maris andOostenveld, 2007) was conducted as implemented in
FieldTrip (http://fieldtrip.fcdonders.nl/; Litvak et al., 2007; Premoli et al.,
2014a; Premoli et al., 2014b). A paired t test was applied to compare the
postdrug versus baseline data within the same drug condition or post-
drug data between different drug conditions for each electrode at each
data point within the five different TOIs. t-values exceeding an a priori
threshold of p  0.05 were clustered based on adjacent data points and
neighboring electrodes. Cluster-level statistics were calculated by taking
the sum of the t-values within every cluster. The statistical comparisons
were done with respect to the maximum values of summed t-values. By
means of a permutation test (i.e., randomizing data across postdrug and
baseline conditions and rerunning the statistical test 1000 times), a ref-
erence distribution of the maximum of summed cluster t-values was
obtained for evaluating the statistics of the actual data. Clusters in the
original dataset were considered to be significant at an  level of 5% if
5% of the permutations used to construct the reference distribution
yielded a maximum cluster-level statistic larger than the cluster-level
value observed in the actual data.
The data from three participants had to be discarded from analysis due
to large artifacts in at least one recording session. Therefore, the pre-
sented TEP data and analyses are based on 15 participants.
Analysis of resting-state EEG data postdrug versus predrug. To investi-
gate drug-induced changes of spontaneous oscillations, 3 min periods of
eyes-closed resting-state EEG (rs-EEG) data recorded postdrug versus
predrug (cf. Fig. 1) were analyzed. Data were preprocessed consistently
with the TEP analysis (see above) and then divided into nonoverlapping
2 s time windows. The power spectra of the rs-EEG signal postdrug and
Figure 2. Grand average TEPs before drug intake. TEPs were averaged over all channels and
artifact-free trials at baseline in the three different drug conditions (100 mg S44819, 50 mg
S44819, and placebo) and labeled based on their polarity (P: positive; N: negative) and approx-
imate latency relative to the time of applying TMS (time 0, vertical dashed line) over the leftM1
(P25, N45, P70, N100, and P180). Topographical distributions of surface voltages illustrated in
the bottom were grand averaged over the three drug conditions in nonoverlapping TOIs after
TMS (P25: 15–35ms; N45: 38–60ms; P70: 63–82ms; N100: 85–119ms; P180: 156–230ms).
Color coding of each map was calibrated according to the maximum positivity (red) and nega-
tivity (blue) of the separate grand-averaged TEPs.
Figure 3. Mean changes (1 SEM) in RMT, AMT, SI0.5mV, and test-MEP (postdrug
baseline) in the three drug conditions (50 mg S44819, 100 mg S44819, and placebo).
The 100 mg S44819 dose decreased AMT and SI0.5mV compared with placebo
(*p 0.05).
Figure 4. Mean SICI intensity curves (shadings:1 SEM) plotted against eight different
conditioning stimulus intensities before (blue) and after (red) intake of S44819 (100 mg; top),
S44819 (50 mg; middle), and placebo (bottom).
Table 1. TMS–EMGmeasures at baseline in the different drug conditions
Measure 100 mg S44819 50 mg S44819 Placebo
RMT (%MSO) 46.00 6.61 45.44 4.88 45.22 5.46
AMT (%MSO) 39.56 5.27 38.94 3.23 38.94 4.29
SI0.5mV (%MSO) 59.50 10.23 58.11 8.37 56.67 9.03
Test-MEP (mV) 0.37 0.08 0.37 0.11 0.34 0.08
Darmani et al. •5-GABAAR Antagonist Effects on Brain Excitability J. Neurosci., December 7, 2016 • 36(49):12312–12320 • 12315
predrug were analyzed in the theta-frequency
(4–7 Hz), alpha-frequency (8–12 Hz), and
beta-frequency (13–30 Hz) bands by means of
Hanning taperwith frequency-dependentwin-
dow length (frequency steps: 1 Hz in the range
4–50Hz). Then, the same cluster statistical test
described previously for TEPs was applied to
the topoplots of the rs-EEG power in the three
bands (postdrug vs predrug; Maris and Oost-
enveld, 2007).
Results
S44819 and all study procedures were
generally well tolerated. Serious adverse
events did not occur.
PK
The mean (SD) peak serum concentra-
tions were 9.09 1.94 ng/ml (range 6.0–
12.6 ng/ml) for 50mg S44819 and 16.47
4.70 ng/ml (range 10.0–28.9 ng/ml) for
100 mg S44819. A model-based PK ap-
proach was used to assess individual and
mean PK parameters. Mean time to peak
concentration (Fig. 1) was 198 min for 50
mg S44819 and 184 min for 100 mg
S44819. These times correspond to 318
min and 314 min, respectively, on the
time axis in Figure 1. Therefore, the time
to peak concentration was reached, on av-
erage, at approximately the end of the
postdrug TMS–EEG recordings and im-
mediately before the postdrugTMS–EMG
recordings.
Drug effects on RMT, AMT, SI0.5mV,
and unconditioned test-MEP amplitude
RMT, AMT, SI0.5mV, and uncondi-
tioned test-MEP amplitude in the SICI
measurements were not different at base-
line between drug conditions (Table 1, all
p 0.05). This ensured that baseline dif-
ferences could not account for any of the
drug effects (see below). Drug effects on RMT, AMT, SI0.5mV,
and unconditioned test-MEP amplitude (postdrug  baseline)
are summarized in Figure 3. Two-way rmANOVAwith the main
effects of time (two levels: baseline and postdrug) and drug con-
dition (three levels: placebo, 50 mg S44819, and 100 mg S44819)
did not reveal any significant main effects or an interaction of
time and drug condition for RMT and test-MEP. In contrast,
AMTand SI0.5mV showed a significant interaction between time
and drug condition (AMT: F(2,34) 	 3.361, p 	 0.047; SI0.5mV:
F(2,34) 	 3.526, p 	 0.041). Post hoc testing revealed that these
effects were explained by a significant decrease in AMT and
SI0.5mV in the 100 mg S44819 condition compared with the
placebo condition (AMT: p	 0.004; SI0.5mV: p	 0.022; Fig. 3).
None of the other post hoc comparisons between drug conditions
was significant. Two-way rmANOVAs with the main effects of
time (two levels: baseline and post drug) and period (period 1,
period 2, and period 3) did not reveal any significant main effect
or interaction of time and period for RMT, AMT, SI0.5mV, or
unconditioned test-MEP, signifying that there were no order
effects.
Drug effects on SICI
The three-way rmANOVA with main effects of time (two levels:
baseline and postdrug), CS intensity (eight levels: 50% to 120%
AMT), and drug condition (three levels: placebo, 50 mg S44819,
and 100 mg S44819) did not reveal any significant interaction
between time and drug conditions (F(2,24)	 1.538, p	 0.235), or
time, drug condition, and CS intensity (F(5.48,65.73)	 0.698, p	
0.640; Fig. 4). Similarly, the three-way rmANOVAwith the main
effects of time, CS intensity, and period (three levels: period 1, pe-
riod 2, and period 3) did not show significant interactions of time
with period, or time, period, and CS intensity, excluding an order
effect.
Drug effects on TEPs
Figure 2 illustrates the grand average TEPs of 15 participants at
baseline in each of the three drug conditions (placebo, 50 mg
S44819, and 100 mg S44819). Five typical TEP components were
identified (P25, N45, P70, N100, and P180) and are shown with
their topographical surface voltages. TEPs were highly reproduc-
ible and there were no differences at baseline between the three
drug conditions.
Figure 5. Grand-averaged TEPs (shadings:1 SEM) elicited by TMS of left M1 before (blue) versus after (red) intake of S44819 (100
mg;A), S44819 (50mg;C), andplacebo (E) or after drug intake comparing S44819 (100mg; red) versus placebo (blue;B) andS44819 (50
mg; red) versus placebo (blue; bottom; D). The 100 mg S44819 dose decreased specifically the N45 TEP component compared with the
baselinemeasurement (A) and comparedwithpostdrugplacebo (B),whereas therewereno changes inother drug conditions and/or TEP
components.HorizontalblackbarsunderneaththeN45denotethesignificantperiodsofdrug-inducedchanges.Dataaregrandaveragesof
those channels that showed a significant difference in the N45 TEP component in the 100 mg S44819 postdrug versus baseline (A) or
betweenthepostdrug100mgS44819andplaceboconditions(B).ThesechannelsareindicatedinFigure6,AandB, respectively.
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The 100 mg S44819 dose suppressed the N45 over the period
of 43–61ms after stimulus (postdrug:0.52 0.27V; baseline:
1.34 0.27V; p 0.05; Fig. 5A). There was also a significant
reduction in the N45 in the postdrug 100 mg S44819 condition
versus postdrug placebo condition over the period 33–55ms after
stimulus (postdrug 100 mg S44819:0.64 0.27 V; postdrug
placebo:2.17 0.38 V; p	 0.01; Fig. 5B). In contrast, there
were no significant differences in postdrug versus baseline in the
placebo (Fig. 5E) or 50 mg S44819 conditions (Fig. 5C) or the
postdrug 50 mg S44819 versus postdrug placebo conditions (Fig.
5D) in any of the TOIs (all p 0.05).
Figure 6 shows the topological distribution of changes in EEG
surface voltage in the N45 component caused by the study drug
(Fig. 6A: postdrug vs baseline 100mg S44819; Fig. 6B: postdrug 100
mg S44819 vs postdrug placebo). Cluster-based analyses revealed
that this significant depression ofN45 amplitude occurred largely in
thenonstimulated right frontal andcentral cortex (postdrugvsbase-
line 100mgS44819:p 0.05, significant channels: FC2, FC6, F2, F4,
F6, C6, and AF8; postdrug 100mg S44819 vs postdrug placebo: p	
0.01, significant channels: FC2, FC6, F2, F4, F6, F8, Cz, C2, C4, C6,
CP2, CP6, and AF8); that is, in a region where the N45 is typically
expressed (cf. Fig. 2 and left columnof Fig. 6). Finally, the individual
N45 data are displayed in Figure 7 to demonstrate the consistency of
the suppressive effect by 100 mg S44819 across subjects. In sum-
mary, results suggest a highly specific effect of S44819; that is, a
selective depression of the N45 TEP component at the dose of 100
mg S44819.
Linear regression analyses were performed to determine
whether the depression in N45 amplitude (postdrug  baseline
100 mg S44819) correlated with the TMS–EMG changes ob-
served for AMT and SI0.5mV.None of these correlations showed
significance (all p 0.05).
Finally, peak 100 mg S44819 serum concentration correlated
with the change in N45 amplitude (postdrug  baseline 100 mg
S44819; Fig. 8, Pearson correlation coefficient r	 0.066, p	 0.015),
but not with the changes in AMT or SI0.5mV (all p 0.05).
Drug effects on rs-EEG power
The cluster-based analysis did not reveal
any significant effect of any of the drugs
on rs-EEG power in any of the frequency
bands (theta-, alpha-, and beta-frequency
bands; all p 0.05).
Discussion
Significant effects of the specific 5-
GABAAR antagonist S44819 on excitabil-
ity of the human cortex could be
demonstrated by TMS–EMG and TMS–
EEG assessments. Main findings were de-
creases in AMT and SI0.5mV and a
reduction specifically of the N45 TEP
component of the TMS-induced EEG re-
sponse, whereas SICI and other TEP com-
ponents remained unaffected. In the
following paragraphs, these findings will
be discussed and interpreted.
Dose effects
All significant effects of S44819 on TMS–
EMG and TMS–EEGmeasures of cortical
excitability were observed only with the
100mg dose, but not with the 50mg dose.
The presence of significant effects strongly
suggests that a single oral dose of 100 mg
S44819 reaches the humanbrain to a relevant extent. All observed
effects are consistent with the notion that 100 mg S44819 in-
creased cortical excitability via reduction of tonic inhibition. Im-
portantly, the decrease in N45 amplitude correlated directly with
the peak serum concentration of 100 mg S44819, suggesting that
the modulation of N45 can be used as a direct marker of S44819
action, most likely on 5-GABAARs, in the human brain.
SICI
S44819 did not change SICI. Several factors likely account for this
nil finding. SICI has been established as a marker for GABAAR-
mediated inhibition (for review, see Ziemann et al., 2015).
Benzodiazepines, allosteric positive modulators of GABAARs
containing 1-, 2-, 3-, or 5-subunits, consistently increased
SICI (Ziemann et al., 1996a; Di Lazzaro et al., 2000; Ilic´ et al.,
2002; Di Lazzaro et al., 2005; Di Lazzaro et al., 2006; Di Lazzaro et
al., 2007; Mu¨ller-Dahlhaus et al., 2008; Teo et al., 2009). There
have been two important specifications to these findings. First,
zolpidem, a benzodiazepine-like hypnotic with largely specific
positive modulation of the 1-GABAAR, had no effect on SICI
(Di Lazzaro et al., 2007; Teo et al., 2009). This suggested that SICI
represents inhibition mediated by GABAARs other than the
1-GABAAR (i.e., the 2-, 3-, and/or 5-subtypes of the
GABAAR). Second, the benzodiazepine antagonist flumazenil
did not change SICI (Jung et al., 2004). This provided evidence
that there is normally no significant endogenous activity at the
benzodiazepine GABAAR-binding site in the human M1.
Furthermore, cortical polarization by anodal or cathodal
transcranial direct current stimulation (tDCS) did not affect SICI
(Nitsche et al., 2005). This is a very important nil finding because
pharmacological blockade of the 5-GABAAR would be ex-
pected to shift the resting membrane potential toward depolar-
ization (similar to anodal tDCS; and see below on the effects of
S44819 on AMT and SI0.5mV). In contrast to the synaptic 1-,
2-, and 3-GABAARs, the 5-GABAAR is localized extrasyn-
Figure 6. Topographical surface voltage plots of the N45 TEP component. A, Topoplots before (left column) and after (middle
column) intake of 100 mg S44819 and t-statistic map (right column) of the postdrug versus baseline differences (postdrug
baseline 100 mg S44819). B, Topoplots of the N45 TEP component after intake of placebo (right column) and S44819 (100 mg;
middle column), and t-statistic map (right column) of the postdrug 100mg S44819 versus post placebo differences (postdrug 100
mg S44819 post placebo). Large crosses on the left hemispheres indicate the site of TMS over left M1. Yellow color on the
t-statistic maps represents a decrease of N45 negativity. Black dots on the t-statistics maps represent the channels showing a
significant difference. Note that these channels are located in the nonstimulated right hemisphere in the region where the N45 is
predominantly expressed.
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aptically (Bru¨nig et al., 2002; Farrant and
Nusser, 2005) and is involved in tonic in-
hibition that decreases pyramidal neuron
excitability (Mitchell and Silver, 2003;
Caraiscos et al., 2004). Because neither in-
tervention (tDCS or S44819) affected
SICI, themost straightforward conclusion
is that SICImeasures specifically synaptic,
but not extrasynaptic, GABAAergic inhi-
bition in humanM1. This conclusion is in
full accordance with the currently ac-
cepted notion that the subthreshold CS of
the SICI paired-pulse protocol excites
low-threshold inhibitory interneurons
that synapse via GABAARs onto pyrami-
dal neurons that are then less excitable to
the succeeding suprathreshold test stimu-
lus (Ilic´ et al., 2002; Di Lazzaro and Zi-
emann, 2013).
Single pulse TMS–EMGmeasures
(RMT, AMT, SI0.5mV, test MEP)
The 100 mg S44819 dose reduced AMT
and SI0.5mV. This suggests that blockade
of extrasynaptic 5-GABAARs increases
the excitability of corticospinal neurons to
single-pulse TMS. This is plausible be-
cause the blockade of extrasynaptic 5-
GABAARs by S44819 will result in a less
hyperpolarized (i.e., more depolarized)
state of pyramidal neurons in M1. Basic
experiments showed that an increase of
tonic inhibition shifts the input–output
relationship of single cells to the right; that
is, the probability of action potential gen-
eration to a given excitatory input is de-
creased (Mitchell and Silver, 2003). At the
systems level, depolarization, probably of
the somatic region of corticospinal cells,
by anodal tDCS over M1 increases MEP
amplitude (Nitsche and Paulus, 2000,
2001;Nitsche et al., 2005).However, RMT
and AMT remain unchanged after anodal
tDCS (Nitsche et al., 2005). In addition,
an increase of ambient GABA in the extra-
cellular space by vigabatrin, an irrevers-
ible inhibitor of the GABA transaminase, or by tiagabine, a
GABA-transporter-blocking GABA reuptake inhibitor, had no
effect on motor thresholds or MEP amplitude (Ziemann et al.,
1996b; Werhahn et al., 1999). However, the change of GABA
concentration at extrasynaptic sites by these drugs may be too
small to drive changes in excitability of corticospinal neurons to
single-pulse TMS. Consistent with the current findings, some,
but not all, of the previous pharmacological TMS–EMG studies
that tested the effects of benzodiazepines reported an increase in
motor threshold (Ilic´ et al., 2002) or a decrease inMEP amplitude
(Di Lazzaro et al., 2000; Boroojerdi et al., 2001). These effectsmay
be explained by the positive modulation of benzodiazepines at
the extrasynaptic 5-GABAAR. S44819 did not affect RMT, but
there was a nonsignificant trend for 100 mg S44819 to reduce
RMT compared with placebo (p	 0.074, cf. Fig. 3). There were
no significant drug effects on the unconditioned test-MEP am-
plitude because test stimulus intensity was adjusted, whenever
necessary, to maintain a test MEP amplitude of, on average 0.5
mV, in the postdrug paired-pulse SICI measurements.
TMS–EEGmeasures of TEPs
The 100 mg S44819 dose reduced the N45 amplitude and the
amount of N45 amplitude reduction was correlated directly with
the peak serum concentration of 100 mg S44819. The effect was
expressed in the frontal and central region of the nonstimulated
right hemisphere, where the N45 potential is predominantly lo-
calized (Komssi et al., 2004; Bonato et al., 2006; Litvak et al., 2007;
Rogasch et al., 2013; Premoli et al., 2014a; Premoli et al., 2014b).
In addition, the effect was specific because none of the other TEP
amplitudes (P25, P70, N100, or P180) was altered by S44819.
Furthermore, the absence of drug effects on rs-EEG power sug-
gests that the observed reduction of N45 amplitude by 100 mg
S44819 cannot be explained by concomitant alterations in rs-
EEG power. The reduction of the N45 amplitude by S44819 is
Figure 7. Drug-induced modulation of the N45 TEP component (single-subject data). Scatter plots of individual amplitude
modulations (A: postdrug baseline; B: postdrug postplacebo) of the N45 for all conditions are illustrated. In all conditions,
datawere extracted fromEEG channels showing a significant difference for postdrug 100mg S44819 baseline S44819 (100mg;
A), or postdrug 100 mg S44819 postplacebo (B). Error bars indicate the group mean1 SEM.
Figure 8. Correlation between the peak 100mg S44819 serum concentration and the change in N45 amplitude (postdrug 100
mgS44819baseline). Pearson correlation coefficient r	 0.66, p	 0.015. The data fromonly 13/15 subjectswere subjected to
this correlation analysis because two subjects had no identifiable N45 potential.
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opposite to the significant increase observed in our previous
studies by single doses of the benzodiazepines alprazolam and
diazepam and the hypnotic zolpidem, a largely selective positive
modulator at the 1-GABAAR (Premoli et al., 2014a; Premoli et
al., 2014b). Because alprazolam, diazepam, and zolpidem exhibit
a common receptor affinity profile targeting the 1-subunit of
the GABAAR, these data strongly suggested that activation of
1-subunit-containing GABAARs contributes to the generation
of the N45 potential. The current findings extend this notion by
providing evidence that the 5-GABAAR also contributes to the
generation of the N45 potential.
The lack of an effect of S44819 on the N100 TEP component
may be explained by the fact that activation of GABABRs, but not
GABAARs, contributes to its generation at the site of its predom-
inant expression in the stimulated M1, as indicated by the signif-
icant increase of the N100 amplitude by baclofen, a selective
GABABR agonist (Premoli et al., 2014b). Furthermore, we had
observed a decrease of the N100 amplitude in our previous stud-
ies by alprazolamanddiazepam, but not zolpidem (Premoli et al.,
2014b). The current findings suggest that the transcallosal and/or
corticothalamo-cortical interactions, which are probably respon-
sible for the modulation of the N100 amplitude in the nonstimu-
lated hemisphere by diazepam and alprazolam, depend on
activation of 2- and/or 3-GABAARs, but not 1- (zolpidem)
or 5-GABAARs (S44819).
Two limitations of this study should be noted: behavioral data
have not been obtained because this study was designed to test
primarily the effects of S44819 on cortical and corticospinal ex-
citability asmeasuredwith TMS–EEGandTMS–EMG.However,
investigation of behavioral measures, in particular on memory
and learning processes that are expected to be influenced by
S44819, and the relation of the currently obtained electrophysio-
logical measures with behavior would be of interest in future
studies. Furthermore, implementation of navigated TMS would
be advantageous to optimize test–retest reliability in future phar-
maco-TMS–EEG studies (Casarotto et al., 2010).
Conclusions
The present data provide evidence that the selective5-GABAAR
antagonist S44819 reached human cortex at a sufficient concen-
tration to impose an increase in corticospinal and cortical excit-
ability, as indexed by a decrease in motor threshold measured by
single-pulse TMS–EMG and a decrease of the amplitude of the
N45 component of the TMS–EEG response. These data warrant
the further development of S44819 in a human clinical trial to test
its efficacy in enhancing recovery of function after ischemic
stroke, in which tonic inhibition mediated by 5-GABAARs is
abnormally increased in the peri-infarct zone.
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Abstract 19 
Brain responses to transcranial magnetic stimulation (TMS) recorded by 20 
electroencephalography (EEG) are emergent non-invasive markers of neuronal 21 
excitability and effective connectivity in humans. However, the underlying 22 
physiology of these TMS-evoked EEG potentials (TEPs) is still heavily 23 
underexplored, impeding a broad application of TEPs to study pathology in 24 
neuropsychiatric disorders. Here we tested the effects of a single oral dose of 25 
three antiepileptic drugs with specific modes of action (carbamazepine, a 26 
voltage-gated sodium channel (VGSC) blocker; brivaracetam, a ligand to the 27 
presynaptic vesicle protein VSA2; tiagabine, a gamma-aminobutyric acid 28 
(GABA) re-uptake inhibitor) on TEP amplitudes in 15 healthy adults in a double-29 
blinded randomized placebo-controlled crossover design. We found that 30 
carbamazepine decreased the P25 and P180 TEP components, and 31 
brivaracetam the N100 amplitude in the non-stimulated hemisphere, while 32 
tiagabine had no effect. Findings corroborate the view that the P25 represents 33 
axonal excitability of the corticospinal system, the N100 in the non-stimulated 34 
hemisphere propagated activity suppressed by inhibition of presynaptic 35 
neurotransmitter release, and the P180 late activity particularly sensitive to 36 
VGSC blockade. Pharmaco-physiological characterization of TEPs will facilitate 37 
utilization of TMS-EEG in neuropsychiatric disorders with altered excitability 38 
and/or network connectivity.  39 
 40 
Keywords 41 
Brivaracetam; carbamazepine; electroencephalography; excitability; human 42 
cortex; tiagabine; TMS-evoked EEG response; transcranial magnetic 43 
stimulation   44 
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Introduction 45 
Many neuropsychiatric disorders are caused by or associated with abnormal 46 
neuronal excitability and/or network connectivity. However, it is still difficult to 47 
measure these abnormalities non-invasively. Transcranial magnetic stimulation 48 
(TMS) evoked electroencephalographic (EEG) potentials (TEPs) provide a 49 
relatively novel technique to test excitability and connectivity of the human brain 50 
(Chung, et al., 2015; Ilmoniemi and Kicic, 2010; Ilmoniemi, et al., 1997; 51 
Rogasch and Fitzgerald, 2013; Ziemann, 2011). However, the physiological 52 
mechanisms underlying TEPs remain heavily underexplored impeding their 53 
clinical application, even though several studies have used them to study a 54 
variety of patients, for instance with epilepsy (Julkunen, et al., 2013; Kimiskidis, 55 
et al., 2017; Shafi, et al., 2015; Ter Braack, et al., 2016; Valentin, et al., 2008), 56 
traumatic brain injury (Bashir, et al., 2012), multiple sclerosis (Zipser, et al., 57 
2018), stroke (Pellicciari, et al., 2018), Alzheimer’s disease (Ferreri, et al., 58 
2016), or depression (Sun, et al., 2016).  59 
When TMS is applied to the primary motor cortex (M1) then a typical sequence 60 
of TEPs can be recorded that are named according to their relative polarity and 61 
latency (in ms): P25, N45, P70, N100, and P180 (Bonato, et al., 2006; Lioumis, 62 
et al., 2009). One way to characterize the physiology of these TEPs is to test 63 
their changes in healthy subjects under challenge with central nervous system 64 
active drugs, which have specific modes action (Ziemann, et al., 2015b). 65 
Neurotransmission through the gamma-butyric acid type A (GABAA) receptor 66 
contributes to the N45 potential because positive modulators at the GABAA 67 
receptor, such as benzodiazepines and zolpidem, and the SV2A ligand 68 
levetiracetam increased the N45 potential amplitude (Premoli, et al., 2017a; 69 
Premoli, et al., 2014a; Premoli, et al., 2017b), whereas S44819, a specific 70 
antagonist of the alpha-5 subunit bearing subtype of the GABAA receptor 71 
decreased it (Darmani, et al., 2016). Moreover, neurotransmission through the 72 
GABAB receptor contributes to the N100 potential because baclofen, a specific 73 
agonist at the GABAB receptor, increased the N100 potential amplitude at the 74 
site of stimulation (Premoli, et al., 2014a). Positive modulators at the GABAA 75 
receptor resulted in a decrease of the N100 potential in frontal areas of the non-76 
stimulated hemisphere, suggesting that propagation of neuronal activity into 77 
areas remote from the stimulation site is under the control of neurotransmission 78 
 
 
4 
through the GABAA receptor (Ferrarelli, et al., 2010; Premoli, et al., 2014a). 79 
Finally, late TEP components, such as the P180 may be controlled by axonal 80 
excitability, as the voltage-gated sodium channel (VGSC) blocker lamotrigine 81 
resulted in a depression of the P180 amplitude (Premoli, et al., 2017b).  82 
 83 
Here we extend previous findings by studying the effects of carbamazepine 84 
(CBZ), brivaracetam (BRV) and tiagabine (TGB) on cortical excitability and 85 
inhibition in healthy human subjects testing both TMS evoked 86 
electromyographic (EMG) and TMS-EEG responses. Drugs were chosen 87 
because of their common use as antiepileptic drugs and well-defined specific 88 
modes of action: CBZ is a VGSC blocker (Macdonald, 1995), BRV decreases 89 
neuronal excitability primarily through selective binding to the presynaptic 90 
vesicle protein SV2A (Klein, et al., 2018; Klitgaard, et al., 2016), and TGB is a 91 
selective GABA reuptake inhibitor (Suzdak and Jansen, 1995). Subjects 92 
received a single oral dose of CBZ, BRV, or TGB in a double-blinded, 93 
randomized, placebo-controlled crossover design. The study was exploratory 94 
but, given the previous pharmaco-TMS-EEG data, we expected suppression of 95 
the P180 under CBZ and, possibly, an increase of N45 under BRV, although the 96 
detailed modes of action of BRV and levetiracetam are different, with 97 
levetiracetam but not BRV showing relevant inhibitory action on glutamatergic 98 
neurotransmission through AMPA and NMDA receptors (Lee, et al., 2009; 99 
Niespodziany, et al., 2017). 100 
We consider this work important to elucidate the physiological underpinnings of 101 
TEPs, potentially to use them in the future as biomarkers to inform on specific 102 
abnormalities in excitability and/or connectivity of human cortex.  103 
  104 
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Materials and Methods 105 
Participants 106 
Fifteen right-handed healthy male volunteers (mean age = 28 years, SD = 2.6 107 
years, age range: 22 – 33 years) were recruited to participate in the study. 108 
Right-handedness was confirmed using the Edinburgh handedness inventory 109 
(laterality score ≥ 75%, (Oldfield, 1971)). All participants gave written informed 110 
consent prior to study enrolment. Participants underwent a physical and 111 
neurological examination followed by a structured clinical interview to exclude 112 
subjects with conditions that would predispose them to potential adverse effects 113 
related to TMS, MRI, or any of the study drugs (Rossini, et al., 2015). The 114 
general exclusion criteria included 1) drug or alcohol abuse, 2) any history of 115 
neurological or psychiatric diseases, 3) a history of cardiac, hematopoietic, liver 116 
and/or kidney disease, 4) current use of CNS active drugs, 5) a family history of 117 
epilepsy, and 6) contraindications to the study medications (CBZ, BRV, and 118 
TGB). To screen for atrioventricular block, a 12-channel ECG was performed at 119 
the inclusion visit. The experiments were conducted in accordance with the 120 
Declaration of Helsinki and approved by the ethics committee of the Medical 121 
Faculty of Eberhard-Karls-University Tübingen (protocol 026/2016BO1).  122 
 123 
Experimental design  124 
The study followed a double-blinded, placebo-controlled crossover design, 125 
measuring motor-evoked potentials (MEPs) and TMS-evoked EEG potentials 126 
(TEPs) in response to single- and paired-pulse TMS of the left M1 hand area 127 
before (pre) and after (post) administration of either of the three study drugs or 128 
placebo. Subjects participated in four experimental sessions in pseudo-129 
randomized order, balanced across subjects, and separated by at least one 130 
week to avoid carry-over effects from the previous session. Study drugs were: 131 
1) CBZ, a VGSC blocker (Macdonald, 1995), 2) BRV, a specific ligand to the 132 
presynaptic vesicle protein SV2A with high affinity and selectivity (Klein, et al., 133 
2018; Klitgaard, et al., 2016), and 3) TGB, a selective GABA re-uptake inhibitor 134 
(Suzdak and Jansen, 1995). The timeline of an experimental session is 135 
illustrated in Figure 1. Resting motor threshold (RMT), the TMS intensity to 136 
elicit MEPs of 1mV peak-to-peak amplitude (SI1mV), short-interval intracortical 137 
inhibition (SICI) intensity curves, MEP input-output curves, resting state EEG 138 
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(rs-EEG), and TMS-evoked EEG potentials (TEPs) were measured prior to 139 
study drug intake (pre-drug measurements) and again following a defined 140 
waiting period after study drug intake (post-drug measurements). 141 
Drug dosages were chosen based on effective standard daily doses in the 142 
(chronic) treatment of epilepsy patients and according to previous TMS-EMG 143 
reports (Sommer, et al., 2012; Werhahn, et al., 1999b; Ziemann, et al., 1996a; 144 
Ziemann, et al., 2015b). Single dosages of either CBZ 600 mg (Carbamazepine 145 
AbZ®, AbZ-Pharma GmbH), BRV 100 mg (Briviact®, UCB Pharma SA), TGB 146 
15 mg (Gabitril®, Cephalon UK Ltd.) or placebo (P-Tabletten Lichtenstein, 147 
Winthrop) were administered (Table 1). A common waiting period of 150 min 148 
was chosen based upon the drugs individual tmax, and upon TMS studies that 149 
previously demonstrated an effect on cortical excitability and/or GABAergic 150 
activity after this waiting period (Werhahn, et al., 1999a; Ziemann, et al., 151 
1996a). Placebo tablets had roughly the same size as CBZ, BRV and TGB, and 152 
subjects were asked to close their eyes before tablet intake in order to prevent 153 
recognition of the tablet by color.  154 
Table 1: Pharmacokinetics for the study drugs and placebo. 155 
Drug Dosage Administration form Median tmax (range) 
Median t1/2 
(range) 
CBZ 600 mg tablet 4.5 (4.0-5.0) 45.0 (25.0-65.0) 
BRV 100 mg tablet 1.0 (0.25- 3.0) 9.0 (N.R.) 
TGB 15 mg tablet 0.75 8.0 (7.0-9-0) 
PBO N.A. tablet N.A. N.A. 
CBZ, carbamazepine; BRV, brivaracetam; TGB, tiagabine; PBO, placebo; Median tmax indicates 156 
time to peak plasma concentrations in hours; Median t1/2 indicates median biological half-life (in 157 
hours) of the substances as given in the full prescribing information of each medication 158 
respectively (resources: US food and drug administration, FDA); N.R., not reported; N.A., not 159 
applicable. 160 
 161 
Prior to the first session, a high-resolution T1-weighted anatomical magnetic 162 
resonance (MR) image (voxel size = 1 × 1 × 1 mm; FoV read = 250, FoV phase 163 
= 93.8%, TR = 2300 ms, TE = 4.18 ms, FA = 9.0°) was obtained from each 164 
subject using a 3T MRI scanner (Magnetom Prismafit, syngo MR D13D; 165 
Siemens) to allow neuronavigation of the TMS coil. In each experimental 166 
session, pre-drug TMS measurements were conducted either at 8:00 am or 167 
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10:30 am (always at the same time for a given participant) after participants had 168 
a light caffeine-free breakfast. One hour after drug intake a cereal bar (without 169 
chocolate) was ingested. During the waiting period subjects were located in the 170 
waiting area of the lab, where they could be monitored constantly (in order to 171 
prevent sleeping and to monitor possible adverse effects). At 1:00 pm or 3:30 172 
pm, respectively, post-drug TMS measurements were started. The total 173 
experimental session time was 6:35 h ± 20 min (mean ± SD). In order to control 174 
for blood pressure changes during the experimental sessions, blood pressure 175 
was measured at the beginning of each session, immediately prior to drug 176 
intake, one and two hours post drug intake, and at the end of the session. All 15 177 
subjects participated in 4 experimental sessions, however, only a subset of 12 178 
subjects was able to complete the experimental session after taking TGB. Three 179 
subjects experienced adverse effects in the TGB session including dizziness, 180 
nausea, vomiting, somnolence, coordination problems, concentration difficulties, 181 
confusion and nervousness. In these subjects, the post drug measurements 182 
could not be obtained.  183 
Experimental procedures and data recording 184 
Transcranial magnetic stimulation (TMS). Subjects were seated in a 185 
comfortable reclining armchair, and watched a fixation point directly in front of 186 
them. To reduce head movement, a vacuum pillow was placed around the neck. 187 
Monophasic TMS pulses were delivered through a 90-mm figure-of-eight coil 188 
using a Magstim 200 stimulator (Magstim Co., Whitland, UK), in case of single-189 
pulse TMS, or two Magstim 200 stimulators connected by a BiStim module, in 190 
case of paired-pulse TMS. To ensure reproducibility of the stimulation site 191 
across sessions, we used a frameless stereotactic neuronavigation system 192 
(Localite GmbH, Sankt Augustin, Germany) to digitize EEG electrode positions 193 
and to navigate the TMS coil based on each subject’s anatomical MRI scan. To 194 
have a comparable EEG cap positioning across sessions, EEG electrode 195 
positions were digitalized at the beginning of the first session individually and 196 
cap position was kept identical in the following sessions with the help of the 197 
stored electrode positions (this is an important step to obtain comparable TEP 198 
results for the different sessions). The TMS coil was placed tangentially to the 199 
scalp and perpendicular to the central sulcus to optimally excite corticospinal 200 
motor neurons in M1 with an induced current direction in the brain from 201 
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posterior to anterior (Di Lazzaro, et al., 2008; Mills, et al., 1992). Then the coil 202 
position was optimized individually to evoke the largest and most consistent 203 
responses (MEPs) in the relaxed abductor pollicis brevis (APB) muscle of the 204 
right hand at a marginally suprathreshold stimulus intensity. The coil was 205 
maintained at the desired position with the help of a holding arm (Magic Arm, 206 
Manfrotto, Cassola, Italy) and coil position was monitored in real-time by the 207 
neuronavigation system to ensure targeting consistency.  208 
Resting motor threshold (RMT) was determined as the lowest stimulation 209 
intensity (in percent maximum stimulator output [MSO]) evoking MEPs of at 210 
least 50 µV peak-to-peak amplitude in at least 5 out of 10 successive trials 211 
(Groppa, et al., 2012). SI1mV was determined as the stimulus intensity required 212 
to evoke average MEPs of 1mV peak-to-peak amplitude in the relaxed APB 213 
muscle. Short interval intracortical inhibition (SICI) was tested by applying 214 
paired-pulse TMS and investigating the effect of a first subthreshold 215 
(conditioning) stimulus on a second suprathreshold (test) stimulus (Kujirai, et 216 
al., 1993). The test stimulus (TS) was delivered at a short interstimulus interval 217 
(ISI) of 2.0 ms after the conditioning stimulus (CS); 2.0 ms was selected since 218 
maximum SICI typically occurs at this ISI and short-interval intracortical 219 
facilitation does not compromise the SICI effect at this particular interval 220 
(Peurala, et al., 2008a; Roshan, et al., 2003; Ziemann, et al., 1998). SICI was 221 
obtained at six different CS intensities (50%, 60%, 70%, 80%, 90%, and 100% 222 
of RMT) with TS intensity set to SI1mV. The amplitude of CS responses was 223 
expressed as percentage of the amplitude of the TS responses. Eight trials for 224 
each CS intensity condition and sixteen trials for the TS alone condition were 225 
delivered in randomized order, i.e., a total of 64 trials. For post-drug 226 
measurements, TS intensity was adjusted to ensure that MEPs in response to 227 
TS alone still showed a 1mV peak-to-peak amplitude on average, despite a 228 
potential drug- or time-related change in corticospinal excitability. This was 229 
important to avoid non-specific alteration of SICI related to changes in test MEP 230 
amplitude (Sanger, et al., 2001). Subjects were provided with audio-­‐‑visual 231 
feedback of APB muscle activity to assist in maintaining complete muscle 232 
relaxation, avoiding any drug-unrelated reduction of SICI by pre-innervation 233 
(Ridding, et al., 1995). MEP input-output curves were also acquired in the 234 
resting APB muscle. Seven stimulus intensities (90%, 100%, 110%, 120%, 235 
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130%, 140%, and 150% of RMT) were tested in randomized order, and eight 236 
trials were obtained per stimulus intensity, resulting in a total of 56 single-pulse 237 
stimuli. For post-drug MEP input-output curves, stimulus intensity was not 238 
adjusted in case of RMT change, i.e., the same absolute stimulus intensities 239 
were used for pre- and post-drug measurements. TMS-evoked EEG potentials 240 
(TEPs) were measured in response to 200 single TMS pulses, delivered at an 241 
intensity of 100% RMT (as determined at baseline), pre- and post-drug intake 242 
with a jittered 4-6 s inter-trial interval to reduced anticipation of the next trial. 243 
Here, post-drug TEP measurements were repeated with an adjusted stimulus 244 
intensity if RMT had changed by more than 2% MSO (Figure 1). Auditory white 245 
noise masking via in-ear headphones was used to attenuate auditory co-246 
stimulation by the TMS click and prevent contamination of TMS-evoked EEG 247 
responses with auditory evoked potentials (Casarotto, et al., 2010; Massimini, et 248 
al., 2005).  249 
 250 
EMG recordings. MEPs were recorded from the APB muscle using EMG 251 
adhesive hydrogel electrodes (Kendall, Covidien) in a bipolar belly-tendon 252 
montage and a ground electrode placed on the right wrist. EMG data were 253 
recorded (20 Hz – 2 kHz bandpass filter, 50 Hz notch filter, 5 kHz sampling rate) 254 
by Spike2 software (Cambridge Electronic Design) and stored for offline 255 
analysis. 256 
 257 
EEG recordings. Subjects were instructed to fixate a cross, minimize eye 258 
blinks, and keep their face and hand muscles relaxed during data recording. 259 
EEG was recorded using a 64-channel EEG cap with TMS-compatible sintered 260 
Ag/AgCl electrodes (Multitrodes, BrainCap-Fast’n Easy; Brain Products). FCz 261 
and AFz served as recording reference and ground electrode, respectively. To 262 
minimize TMS-related artifacts during TEP measurements, EEG signals were 263 
recorded in DC mode with an anti-aliasing low-pass filter of 1000 Hz, and 264 
digitized with a resolution of 0.1 µV/bit at a sampling rate of 5 kHz using 265 
BrainVision Recorder software (version 1.20; BrainProducts). Additional 266 
electrodes for horizontal and vertical electrooculography were placed at the 267 
outer canthus and below of the right eye to monitor eye movement artifacts. The 268 
position of each EEG electrode relative to the head was recorded and stored 269 
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using the neuronavigation system to allow precise repositioning of the cap for 270 
subsequent sessions of the same subject. Electrode impedances were regularly 271 
checked and kept below 5 kΩ throughout the experiment. In each experimental 272 
session, 5 min of both, eyes-closed and eyes-open resting-state EEG were 273 
acquired additional to TEP recordings before and after drug intake to investigate 274 
drug-induced changes in spontaneous oscillatory brain activity.  275 
 276 
Data analyses 277 
TMS–EMG analysis. EMG data were analyzed blind to experimental conditions 278 
using customized MATLAB scripts (R2015a, MathWorks). Data were imported 279 
from Spike2 to MATLAB and MEP peak-to-peak amplitudes were determined 280 
per trial and averaged across trials per time point (pre, post drug) and drug 281 
condition. For assessment of drug-induced changes in RMT and SI1mV, 282 
normalized (post/pre) data were computed separately for all drug conditions, 283 
and two-sided one-sample t-tests against 1 for each drug condition and two-284 
sided paired t-tests for comparing drug conditions with placebo were conducted. 285 
MEP input-output curves were obtained by calculating conditional averages (7 286 
stimulation intensity levels: 90% - 150% RMT in steps of 10% RMT) of the 287 
peak-to-peak MEP amplitudes. SICI intensity curves were calculated as the 288 
ratio of conditional averages of conditioned MEP (6 CS intensities: 50% - 100% 289 
RMT in steps of 10% RMT) over the average test MEP (TS intensity: SI1mV). 290 
For MEP input-output and SICI intensity curves, three-way rmANOVAs were 291 
conducted separately for each study drug relative to placebo, with the factors 292 
TIME (2 levels: pre-drug, post-drug), DRUG (2 levels: drug, placebo), and 293 
INTENSITY (7 levels for MEP input-output curves; 6 levels for SICI intensity 294 
curves). In addition, a two-way rmANOVA with the factors TIME and 295 
INTENSITY was conducted within each drug condition. Post-hoc paired t-tests 296 
were applied in case of significant main effects. Significance threshold was set 297 
to p < 0.05.  298 
 299 
TMS-EEG analysis. EEG data were analyzed blind to experimental conditions 300 
using MATLAB and the Fieldtrip open source toolbox 301 
(www.ru.nl/fcdonders/fieldtrip; (Oostenveld, et al., 2011)), and in accordance with 302 
established artifact removal pipelines (Herring, et al., 2015; Rogasch, et al., 303 
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2017). Raw data were initially segmented into longer epochs from 1.5 s before 304 
to 1.5 s after the TMS pulse to avoid filter artifacts before later reducing 305 
segments to the actual epoch of interest (i.e., from -100 ms to 300 ms after the 306 
TMS pulse). Long epochs were baseline corrected by subtracting the average 307 
of the interval from -220 ms to -20 ms. The initial TMS pulse artifact (amplifier 308 
ringing and step artifact) and subsequent cranial muscle artifacts (resulting from 309 
co-stimulation of peripheral motor nerves) were cut and data was cubically 310 
interpolated between -2 ms to 12 ms. Then, trials and channels were inspected 311 
visually using the summary function of Fieldtrip to remove artifact-contaminated 312 
trials. On average, 37± 23 (mean ± SD) trials were removed per block of 200 313 
trials. Subsequently, a 2 Hz 4th order zero-phase (two-pass) Butterworth high-314 
pass filter were applied to suppress low-frequency fluctuations, followed by 315 
demeaning and downsampling EEG data to 1 kHz. Note that high-pass filtered 316 
and down-sampled data was used for independent component analysis training 317 
only (see below). Independent component analysis (FastICA) was applied to the 318 
down-sampled data to capture the residual muscle and exponential decay 319 
artifacts as well as sharp edges caused by interpolation of the pulse artifact. 320 
Artifact components were identified based on the topography and temporal 321 
pattern of the TMS-locked responses and in agreement with published 322 
procedures (Herring, et al., 2015; Rogasch, et al., 2017). After identifying 323 
artifact contaminated components (on average 3 ± 2 (mean ± SD) per subject), 324 
the same unmixing matrix was applied to the interpolated EEG signal before 325 
high-pass filtering and down-sampling had been applied, and bad components 326 
were removed from those data before back-projection into channel space. This 327 
procedure prevented filter and down-sample artifacts to contaminate our data. 328 
Then, a second round of high-pass filtering (2 Hz), demeaning, downsampling 329 
(1 kHz), and ICA was applied to identify and remove other TMS-unrelated 330 
artifacts such as eye blinks, eye movements, line noise, and tonic muscle 331 
artifacts according to standard criteria (Chaumon, et al., 2015). Again, the 332 
unmixing matrix was applied to the signal cleaned by the first ICA before the 333 
second round of high-pass filtering and downsampling had been applied, and 334 
the selected artefactual components were removed before back-projecting that 335 
signal into channel space. Finally, time-locked averages (TEPs) of the 336 
remaining artifact-free trials (163 ± 23 (mean ± SD) per participant and 337 
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measurement) were computed per measurement time point and drug condition 338 
for each channel, and eventually a 2 Hz high-pass filter and a 45 Hz low-pass 339 
filter were applied followed by baseline correction from -200 to 0 ms and re-340 
referencing of EEG data to the common average of all EEG channels.  341 
Five TEP components: P25 (time window of interest [TOI]: 15–35 ms), 342 
N45 (36–50 ms), P70 (51–85 ms), N100 (86–150 ms), and P180 (151–280 ms) 343 
were studied due to their high reproducibility for M1 stimulation, and in 344 
accordance with the literature (Bonato, et al., 2006; Darmani, et al., 2016; 345 
Lioumis, et al., 2009; Premoli, et al., 2014a; Premoli, et al., 2014b). The specific 346 
TOIs were chosen around the respective peaks based on grand-average TEPs. 347 
Two-tailed paired t-tests were applied to compare pre- and post-drug TEP peak 348 
amplitudes within each drug condition and to test for the interaction between 349 
TIME and DRUG, i.e. drug(post-pre)–placebo(post-pre) for each electrode and 350 
at each time point, separately for the five TOIs. Non-parametric, cluster-based 351 
permutation statistics (Maris and Oostenveld, 2007) were used to control for 352 
multiple comparisons across channels and time points within TOIs. Clusters 353 
were defined as adjacent time point-channel pairs for which the t-statistic 354 
exceeded a threshold of p < 0.05. Cluster-level statistics were calculated based 355 
on the sum of t-values within each cluster. Monte Carlo p-values were 356 
computed based on 10000 random permutations and a value of p < 0.05 was 357 
used as the cluster-statistical significance threshold for all tests.  358 
Since there were strong drug-induced increases in spontaneous 359 
oscillatory power in the post-TGB measurement, which contaminated the TEPs, 360 
we used General Eigenvalue Decomposition (GEiD) for extracting and removing 361 
the spontaneous oscillatory components from the concatenated pre- and post-362 
drug measurements of the TGB session only (Cohen, 2017). Given that delta 363 
and theta frequency bands demonstrated the largest increase, we used the 364 
respective peak frequencies for each subject (as determined from the individual 365 
Fast Fourier Transform (FFT); see below) to individualize the targeted 366 
frequency band for optimal results. Separate GEIDs were calculated for each 367 
frequency band. To identify truly endogenous oscillations, time-frequency 368 
representation, inter-trial coherence, and power spectra of the components 369 
were considered. However, to ensure that spontaneous oscillatory components 370 
were removed to the maximal possible degree, we were very conservative with 371 
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respect to the components kept, which may have resulted in slight 372 
overcorrection and removal of actual TEP components.  373 
 374 
Pre-TMS EEG analysis. To further investigate the above mentioned drug-375 
induced changes of spontaneous oscillations, a FFT was performed for the pre-376 
TMS time periods. Data preprocessed for the TEP analysis between -1030 ms 377 
and -30 ms before the TMS pulse were analyzed using a Hanning-tapered FFT 378 
for frequency bins from of 1 to 45 Hz in steps of 1 Hz, averaged across trials, 379 
separately for each channel, measurement time point and drug condition, and 380 
eventually as grand-average across all participants. The same cluster statistical 381 
test outlined for the TEP analysis was used to test post-drug vs. pre-drug for 382 
each drug condition, as well as the interactions between TIME and DRUG, i.e. 383 
drug(post-pre)–placebo(post-pre), separately for each frequency band: i.e., 384 
delta (1–3 Hz), theta (4–7 Hz), alpha (8–12 Hz), and beta (13–30 Hz). 385 
 386 
Resting-state EEG analysis. In addition to the pre-TMS analyses, we also 387 
quantified drug-induced changes in spontaneous oscillations for the 5 min eyes-388 
open resting-state EEG. For initial ICA pre-processing, rs-EEG data were 389 
segmented into 4 s epochs, and concatenated across all drug conditions and 390 
measurements per subject. Data were 2 Hz high-pass filtered, demeaned, and 391 
down-sampled (1 kHz), and ICA was conducted to identify eye blinks, eye 392 
movements, or muscle/movement artifacts. Similar to the TEP analysis 393 
described above, the unmixing matrix was then applied to the original data 394 
before high-pass filtering and down-sampling. The artefactual components were 395 
removed before back-projection into channel space. Data were visually 396 
inspected, and trials contaminated by residual artifact were removed manually. 397 
The cleaned rs-EEG data were then re-referenced to the average of all EEG 398 
channels. Power spectra were determined via a Hanning-tapered FFT for 399 
frequency bins from 1 to 45 Hz in steps of 0.25 Hz, and spectra were averaged 400 
across segments and EEG channels. Cluster-based permutation tests were 401 
performed as described above separately for delta, theta, alpha and beta 402 
frequency bands. 403 
Results 404 
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CBZ and BRV had tolerability profiles comparable to placebo. TGB, however, 405 
was associated with considerable side effects (see Methods section), causing 3 406 
out of 15 participants to abort the respective session, leading to a reduced 407 
sample size of N = 12 for the analyses of this condition.  408 
Drug effects on RMT and SI1mV 409 
Drug effects on RMT and SI1mV (post-drug/pre-drug) are summarized in 410 
Figure 2 and Table 2. CBZ increased RMT and SI1mV, both with respect to 411 
pre-drug baseline (RMT: t14 = 3.57, p = 0.003; SI1mV: t14 = 4.34 p < 0.001) and 412 
compared to placebo-related changes (RMT: t14 = 3.38, p = 0.004; SI1mV: 413 
t14 = 1.9, p = 0.08, non-significant). Under BRV, there was a non-significant 414 
(p < 0.1) RMT increase relative to both pre-drug baseline (t14 = 1.86, p = 0.08) 415 
and compared to placebo-related changes (t14 = 1.84, p = 0.08), as well as a 416 
significant increase in SI1mV relative to pre-drug baseline (t14 = 2.35, p = 0.03). 417 
No significant effects were found for TGB (RMT: all p > 0.7; SI1mV: all p > 0.3) 418 
or placebo (all p > 0.5). 419 
 420 
Table 2. Mean ± SD for RMT and SI1mV before (pre) and after (post) drug intake for all drug 421 
conditions. 422 
 
CBZ BRV TGB PBO 
pre-drug post-drug pre-drug post-drug pre-drug post-drug pre-drug post-drug 
RMT 
(%MSO) 
42±7.2 45±7.9 41.8±7.2 42.5±6.8 43.4±6.7 43.3±6.9 42.4±6.8 42.4±7 
SI1mV 
(%MSO) 
56±11.1 60.3±11.6 55.4±9.6 58±11.4 57.1±10.8 58.9±12.3 55.7±11.4 56.2±11.3 
CBZ, carbamazepine; BRV, brivaracetam; TGB, tiagabine; PBO, placebo.  423 
 424 
Drug effects on MEP input-output curve 425 
Drug effects on MEP input-output curves are illustrated in Figure 3. A 2x2x7 426 
three-way rmANOVA with factors TIME (pre vs. post), DRUG (drug vs. 427 
placebo), and INTENSITY (90, 100, 110, 120, 130, 140, 150 % RMT) revealed 428 
a main effect of DRUG for CBZ (F1,392 = 5.47, p = 0.02), and a TIME x DRUG 429 
interaction for BRV (F1,392 = 4.45, p = 0.03). A follow-up within-drug 2x7 two-way 430 
rmANOVA for BRV with the factors TIME and INTENSITY did reveal a non-431 
significant (p < 0.1) main effect of TIME only (F1,392 = 3.68, p = 0.056), 432 
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suggesting a general BRV-induced decrease in corticospinal excitability, 433 
irrespective of stimulation intensity. No significant change of MEP input-output 434 
curves was found for TGB or placebo. Trivially, all main effects of INTENSITY 435 
were highly significant (p < 0.0001).  436 
 437 
Drug effects on SICI intensity curve 438 
SICI intensity curves per drug condition (TS intensity adjusted for SI1mV 439 
changes, CS intensity non-adjusted, see Methods) are provided in Figure 4. A 440 
2x2x6 three-way rmANOVA with factors TIME, DRUG, and CS-INTENSITY (50, 441 
60, 70, 80, 90, 100 % RMT) revealed a significant interaction between TIME 442 
and DRUG (F1,336 = 5.24, p = 0.02) for CBZ. A follow-up within-drug 2x6 two-443 
way rmANOVA for CBZ with the factors TIME and CS-INTENSITY for the CBZ 444 
session, revealed main effects of TIME (F1,168 = 8.95, p = 0.003) but no 445 
interaction effect (p > 0.3), indicating a general CBZ-induced decrease in SICI, 446 
irrespective of CS-INTENSITY. For BRV, the three-way rmANOVA revealed a 447 
main effect of DRUG only (F1,336 = 3.9, p = 0.04) but no interaction effect (p > 448 
0.3), and the respective two-way rmANOVA for the BRV session showed no 449 
significant main effect of DRUG or interaction (p > 0.3). No significant change of 450 
SICI intensity curves was found for TGB or placebo. As expected, CS-451 
INTENSITY effects were highly significant in all drug conditions (p < 0.0001). 452 
 453 
Drug effects on TEPs 454 
Cluster-­‐‑based permutation analysis was used to test for differences between 455 
pre-drug TEPs across drug conditions, drug-induced TEP changes within each 456 
drug condition (i.e., post-drug – pre-drug; indicated as vs. baseline in the 457 
following), and drug-induced TEP changes relative to placebo (i.e., the 458 
interaction contrast drug(post-pre)-placebo(post-pre); indicated as vs. placebo 459 
in the following). Because CBZ increased RMT in some subjects, TEP analyses 460 
were conducted for the measurements with adjusted and non-adjusted 461 
stimulation intensity (see Methods). Note that in the following increases and 462 
decreases of TEP components always refer to a modulation of their amplitude 463 
in absolute values (e.g., a decreased N100 means a negative potential of 464 
reduced amplitude). Also note that the same TEP component can have 465 
opposite signs (direction of deflection) in different channels as a result of the 466 
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dipole orientation of the underlying neuronal source and the common average 467 
referencing (e.g., the P25 being positive over the stimulated sensorimotor 468 
cortex, but negative at contralateral posterior sites, with a reduction in absolute 469 
amplitude of that negativity at contralateral posterior sites would still being 470 
considered a decrease of the very same potential).  471 
Figure 5 shows the grand average TEPs at pre-drug baseline for all drug 472 
conditions. In line with the literature, five classic TEP components (P25, N45, 473 
P70, N100, and P180) were identified and selected for further analysis. 474 
Importantly, pre-drug TEPs did not differ between drug conditions, 475 
demonstrating reliability of TMS-evoked EEG responses in our neuronavigated 476 
multi-session TEP measurements. Moreover, there was no significant 477 
modulation of the TEP over time in the placebo condition, besides a non-478 
significantly (p < 0.1) increased P25 amplitude over the stimulated left 479 
sensorimotor cortex (p = 0.06), possibly reflecting a general effect of time, that 480 
is taken into account by analysis of the interaction contrasts (drug(post-481 
pre)-placebo(post-pre)). 482 
 483 
CBZ modulated both early and late TEP components as depicted in Figure 6 484 
(Supplementary Table S1 provides the individual channels for each of the 485 
significant clusters mentioned below) and in Figure 8A. Notably, those changes 486 
were independent of the general decrease in corticospinal excitability (as 487 
reflected by an increase in RMT and SI1mV in the TMS-EMG measurements), 488 
as the following results were obtained with the adjusted stimulation intensity. 489 
CBZ suppressed the P25 potential over the stimulated left sensorimotor cortex 490 
(vs. placebo: p = 0.003; vs. baseline: p = 0.08) and the parieto-occipital cortex 491 
in the non-stimulated right hemisphere (vs. placebo: p = 0.0001; vs. baseline: 492 
p = 0.001). CBZ also caused a reduction of the P180 potential (vs. placebo: 493 
p = 0.03; vs. baseline: p = 0.0005) and a non-significant (p < 0.1) attenuation of 494 
the N100 potential (vs. placebo: p = 0.09; vs. baseline: p = 0.09), both over the 495 
non-stimulated right sensorimotor cortex. The N100 potential was also 496 
decreased in amplitude over the occipito-parietal cortex (vs. placebo: p = 0.058; 497 
vs. baseline: p = 0.03). Notably, without readjustment of the stimulation 498 
intensity, results remained largely identical for the P25 and P180 potential (see 499 
Supplementary Table S1); merely the non-significant (p < 0.1) N100 did not 500 
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survive, and instead the N45 potential was increased over the stimulated left 501 
sensorimotor cortex (vs. placebo: p = 0.03; vs. baseline: p = 0.09) and over the 502 
non-stimulated right sensorimotor cortex (vs. placebo: p = 0.0006; vs. baseline: 503 
p = 0.10) (as shown in Supplementary Figure S1). 504 
 505 
BRV only modulated late TEP components as depicted in Figure 7 and 506 
Supplementary Figure S2 (Supplementary Table S2 provides the individual 507 
channels for each of the significant clusters mentioned below) and in Figure 508 
8B. BRV decreased the N100 potential (vs. placebo: p = 0.03; vs. baseline: 509 
p = 0.03) and caused a non-significant (p < 0.1) attenuation of the P180 510 
potential (vs. baseline: p = 0.08), with drug-induced changes of both TEP 511 
components topographically being located over the non-stimulated right 512 
sensorimotor cortex.  513 
For TGB, in the reduced sample of N = 12 subjects, and despite all attempts to 514 
remove the increased spontaneous oscillatory activity corrupting TEP averages 515 
(see Methods, and below), no significant modulation of any of the TEP 516 
components could be observed (all p ≥ 0.2). 517 
Drug effects on spontaneous oscillations   518 
Drug-induced changes in spontaneous oscillatory spectral power in the pre-519 
TMS time periods are shown in Figure 9 and Supplementary Figure S3. CBZ 520 
caused an increase in the power of spontaneous oscillations that was significant 521 
only for a circumscribed central cluster in the beta band during pre-TMS EEG 522 
periods (vs. placebo: p = 0.007; vs. baseline: p = 0.0009), but extended to more 523 
widespread global increases in the theta (vs. baseline: p = 0.004) and alpha 524 
(vs. placebo: p = 0.004; vs. baseline: p = 0.01) bands in addition to the beta 525 
band (vs. placebo: p = 0.04; vs. baseline: p = 0.01) during eyes open resting-526 
state EEG recordings. 527 
TGB caused an even stronger broadband and spatially widespread boost of 528 
oscillatory spectral power, including delta (vs. placebo: p = 0.0009; vs. baseline: 529 
p = 0.0009), theta (vs. placebo: p = 0.0009; vs. baseline: p = 0.0009), alpha 530 
(vs. placebo: p = 0.0009; vs. baseline: p = 0.01), and beta (vs. placebo: 531 
p = 0.003; vs. baseline: p = 0.0009) bands during both pre-TMS time periods 532 
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and eyes open resting-state EEG. Oscillatory power changes were most 533 
pronounced (i.e. 7-8 fold) in the delta and theta bands (see Figure 9 and 534 
Supplementary Figure S3). 535 
No significant modulation of spontaneous resting EEG spectral power was 536 
observed for BRV or placebo in any of the four frequency bands (all p > 0.2).   537 
 538 
Discussion 539 
The novel findings of this work relate to the drug induced changes in TMS-540 
evoked EEG potentials (TEPs). In the context of previous studies that 541 
investigated the effects of drugs with other specific modes of action this allows 542 
to further characterize the pharmaco-physiology of TEPs, which are considered 543 
important non-invasively measured signatures of excitability and connectivity of 544 
the human brain (Chung, et al., 2015; Rogasch and Fitzgerald, 2013). In the 545 
following the main reported drug effects on TMS-EMG and TMS-EEG measures 546 
will be discussed.  547 
TMS-EMG results 548 
RMT and SI1mV. CBZ increased RMT and SI1mV. This confirms previous 549 
TMS-EMG findings that consistently demonstrated that CBZ increases motor 550 
threshold (for review see (Ziemann, et al., 2015a)). Motor threshold depends on 551 
membrane excitability, and blockade of VGSCs decreases the axonal 552 
excitability of cortico-cortical and corticospinal neurons to single-pulse TMS. 553 
VGSCs are crucial in regulating axon excitability and their blockade will result in 554 
a more hyperpolarized (i.e., less excitable) state of cortico-cortical axons in M1 555 
(Hodgkin and Huxley, 1952), and since these axons have synaptic contacts with 556 
cortico-spinal neurons, VGSC blocking drugs such as CBZ increase motor 557 
threshold (Ziemann, et al., 2015b). 558 
BRV increased the SI1mv and there was also a non-significant (p < 0.1) 559 
increase in RMT, however, the increases in SI1mv and RMT after BRV were 560 
less pronounced than after CBZ, which was expected since BRV has primarily 561 
neurotransmitter-modifying properties. There is some inconsistency in the 562 
reports after levetiracetam intake (also a ligand to the presynaptic vesicle 563 
protein SV2A), with some studies reporting an increase in motor threshold 564 
(Premoli, et al., 2017b; Solinas, et al., 2008), while others reported no change 565 
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(Heidegger, et al., 2010). The slight increase in motor threshold after BRV 566 
intake reported here may relate to a secondary mode of action of BRV in 567 
blocking VGSCs (Niespodziany, et al., 2015). 568 
TGB didn’t alter RMT or SI1mv, in line with previous results (Werhahn, et al., 569 
1999a). 570 
MEP input-output curve. CBZ didn’t change the MEP amplitudes. MEP input-571 
output curve is a measure of trans-synaptic excitation of corticospinal neurons 572 
regulated by glutamatergic, GABAergic and neuromodulating neurotransmitters, 573 
but no effects of ion channels on MEP amplitudes have been established 574 
(Ziemann, et al., 2015b). Note that significant changes in motor threshold may 575 
occur without changes in MEP amplitudes, which supports the idea that the 576 
mechanism underlying motor threshold and MEP amplitudes are different, and 577 
this may explain the lack of a significant effect of CBZ on MEP input-output 578 
curve despite its effects on motor threshold. Also note that the assessment of 579 
changes in RMT and MEP curve, was not only based on two independent 580 
measurements, and determined by two very different procedures, but also relied 581 
on different statistical tests (paired t-tests vs. three-way rm-ANOVA), which may 582 
partially explain this apparent discrepancy. In fact, if conducting post-hoc 583 
comparisons per intensity condition (which is not justified given the lack of 584 
interaction in the three way ANOVA) the single significant post-pre difference 585 
would have been at 100% RMT, but no other intensity. Others have described a 586 
rightward shift of the MEP input-output curve reflecting the increase in motor 587 
threshold after VGSC blocker intake (Boroojerdi, et al., 2001). 588 
BRV produced a non-significant (p < 0.1) decrease in the MEP input-output 589 
curve. This effect may be explained by its specific binding to the presynaptic 590 
vesicle protein SV2A. This protein is expressed on excitatory and inhibitory 591 
neurons throughout the central nervous system (Klein, et al., 2018), but BRV 592 
may exert its antiepileptic effects predominantly through depression of 593 
excitatory neurotransmission (Yang, et al., 2015).The current BRV findings are 594 
in agreement with previous TMS-EMG studies that reported a depression of 595 
MEP input-output curves under levetiracetam (Reis, et al., 2004; Sohn, et al., 596 
2001). 597 
TGB didn’t modulate the MEP input-output curve, in accord with previous 598 
findings (Werhahn, et al., 1999a).  599 
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SICI intensity curve. SICI reflects synaptic GABAAergic inhibition of 600 
corticospinal neurons, and VGSC blockers had no effect on SICI in previous 601 
studies (Ziemann, et al., 2015b). The observed decrease in SICI after CBZ in 602 
the present study (cf. Figure 4) is most likely simply a rightward shift of the SICI 603 
input-output curve caused by the increase in RMT, for which CS intensity was 604 
not adjusted for and, therefore, a non-specific finding. This is supported by the 605 
observation that motor and SICI thresholds are closely related to each other 606 
(Ziemann, et al., 1996b).   607 
BRV had no effect on SICI. This is in accord with the literature where 608 
levetiracetam also did not alter SICI (Reis, et al., 2004; Sohn, et al., 2001; 609 
Solinas, et al., 2008), and with the mode of action of BRV and levetiracetam 610 
without any modulating activity directly at the GABAA receptor (Klein, et al., 611 
2018; Lyseng-Williamson, 2011). 612 
In contrast to previous work (Werhahn, et al., 1999a), we did not observe a 613 
depression of SICI after TGB intake. Those authors also demonstrated a 614 
prolongation of the cortical silent period (CSP) duration and an increase in long-615 
interval intracortical inhibition, both putative measures of GABAB receptor 616 
mediated cortical inhibition (McDonnell, et al., 2006; Ziemann, et al., 2015b), 617 
and interpreted the TGB-induced reduction in SICI through enhanced GABAB 618 
receptor-mediated presynaptic autoinhibition (Werhahn, et al., 1999b). We have 619 
not tested here TMS-EMG measures of GABAB receptor-mediated inhibition, 620 
and there are other methodological differences between the two studies, for 621 
example the ISI of 3 ms (Werhahn, et al., 1999b) vs. 2 ms (our study) for SICI 622 
testing that may have contributed to the disparate findings (Peurala, et al., 623 
2008b).  624 
 625 
TMS-EEG results 626 
Carbamazepine. After application of repetitive TMS (rTMS) or transcranial direct 627 
current stimulation (tDCS), which modulate synaptic strength and cortical 628 
excitability as indicated by TMS-EMG measures (Ziemann, et al., 2008), only 629 
early components of TEPs changed significantly (Esser, et al., 2006; Pellicciari, 630 
et al., 2013; Veniero, et al., 2012). Also, Ilmoniemi et al. showed that after 631 
stimulating M1, motor cortical areas responded within the first 28 ms (Ilmoniemi, 632 
et al., 1997) and these results suggest that the amplitude of early TEPs (< 633 
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30ms) might be a putative marker of excitation of the corticospinal system. 634 
Moreover, the amplitude of the N15-P30 complex correlated directly with MEP 635 
amplitude (Mäki and Ilmoniemi, 2010). In patients with progressive myoclonus 636 
epilepsy, the P25 waveform was increased as a sign for corticospinal and 637 
cortico-cortical hyperexcitability (Julkunen, et al., 2013). Therefore, P25 638 
suppression by CBZ, predominantly at the site of stimulation, most likely reflects 639 
reduction of corticospinal excitability, a finding that remained significant even 640 
with stimulation intensity adjusted to RMT change (Figure 5). This corroborates 641 
the previously established notion that TMS-EEG measures may be more 642 
sensitive than TMS-EMG measures in detecting change in cortical excitability 643 
after intervention (Ferreri and Rossini, 2013). The N15-P30 complex has been 644 
reported to be strongly affected by TMS coil orientation (Bonato, et al., 2006). 645 
However, we were able to exclude this possible confound by careful application 646 
of neuronavigated TMS.  647 
A decrease of N100 was observed after administration of diazepam and 648 
alprazolam, while baclofen increased N100, suggesting that the N100 is 649 
negatively related to GABAA but positively to GABAB receptor mediated 650 
neurotransmission (Premoli, et al., 2014a; Premoli, et al., 2014b). The non-651 
significant (p < 0.1) reduction of N100 amplitude after CBZ should be 652 
considered with caution because it took place only when compared to baseline 653 
but not when compared to placebo, and not with unadjusted stimulus intensities 654 
(Figure 6, Supplementary Figure S1). Therefore, we consider this a nil finding, 655 
that is in accordance with a lacking effect on the N100 by lamotrigine, another 656 
VGSC blocker (Premoli, et al., 2017b).  657 
A decrease in P180 amplitude was observed after lamotrigine intake, both with 658 
and without adjusting stimulus intensity to compensate for RMT change 659 
(Premoli, et al., 2017a; Premoli, et al., 2017b). Our results complement these 660 
findings, as CBZ reduced P180 amplitude both with and without adjusting 661 
stimulation intensity. These results suggest that P180 is reactive to excitability-662 
lowering drugs, e.g., classic VGSC blockers (CBZ and lamotrigine), while 663 
GABAergic drugs had no effect (Premoli, et al., 2014a).  664 
Part of the P180 component is likely caused by auditory evoked activity induced 665 
by the click of the stimulating coil (Conde, et al., 2018; Rogasch, et al., 2014). 666 
Therefore, it is possible that a reduction of the cortical auditory evoked potential 667 
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after CBZ has contributed to the observed P180 reduction. This is, however 668 
unlikely, given the findings in the literature that have only shown changes in 669 
latency but not amplitude of cortical auditory evoked potentials after CBZ 670 
(Japaridze, et al., 1993) but significant amplitude depression after diazepam 671 
(Noldy, et al., 1990). This double dissociation with the reported TMS-EEG P180 672 
data strongly suggests that the reported depression by VGSC blockers is 673 
caused by their effects on direct TMS-evoked brain responses rather than brain 674 
activity related to the auditory input.  675 
 676 
Brivaracetam. The N100 is thought to be a marker of GABABergic inhibition due 677 
to the enhancing effect of baclofen, a specific GABAB receptor agonist, on 678 
N100 amplitude at the site of stimulation (Premoli, et al., 2014a). On the other 679 
hand, benzodiazepines (Premoli, et al., 2014a) and levetiracetam (Premoli, et 680 
al., 2017a) resulted in N100 amplitude depression in the non-stimulated 681 
hemisphere. The present results of BRV, showing N100 amplitude depression 682 
in M1 area of the non-stimulated hemisphere (Figure 7) are in full agreement 683 
with those previous findings. The underlying physiology of this effect, 684 
particularly on propagated neuronal activity remote from the site of stimulation 685 
remains unclear, but may indicate a suppression of long-range cortico-cortical 686 
effective connectivity and signal propagation under the influence of drugs with 687 
positive modulation at the GABAA receptor (Ferrarelli, et al., 2010; Sarasso, et 688 
al., 2015) and drugs with inhibition of presynaptic excitatory transmitter release 689 
(levetiracetam, BRV).  690 
 691 
Tiagabine. TGB didn’t modulate any of the TEP components. One possible 692 
reason might be that the TGB dose was not sufficient to cause any effects. 693 
However, this can be largely excluded as one previous study found significant 694 
effects on TMS-EMG measures with the same dose (15 mg) (Werhahn, et al., 695 
1999b). Furthermore, we found that TGB strongly increased pre-TMS EEG 696 
power in all frequency bands (Figure 9 and Supplementary Figure S3), 697 
confirming findings of two resting-state magnetoencephalographic studies 698 
(Muthukumaraswamy and Liley, 2018; Nutt, et al., 2015) and, therefore, 699 
indicating a significant effect of TGB on brain activity in the present 700 
experiments.  701 
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Nutt and colleagues also had investigated gaboxadol, a positive modulator 702 
specifically at the extrasynaptic alpha-4 delta unit bearing subtype of the 703 
GABAA receptor, and zolpidem, a positive modulator with strong positive 704 
modulating activity at the synaptic alpha-1 unit bearing subtype of the GABA 705 
receptor. Gaboxadol but not zolpidem resulted in a similar enhancement of 706 
resting-state activity as TGB, and they concluded that the effects by TGB may 707 
therefore be largely related to its action on tonic inhibition mediated by 708 
extrasynaptic GABAA receptors (Nutt, et al., 2015). However, this is unlikely to 709 
be the reason for the nil findings of TGB on TEP amplitudes in the present study 710 
as previous studies demonstrated significant effects of ethanol, another positive 711 
modulator at the extrasynaptic alpha-4 delta unit bearing subtype of the GABAA 712 
receptor (Kahkonen, et al., 2001; Kahkonen, et al., 2003).  713 
The reason for the nil findings may be explained by the specific mode of action 714 
of TGB, which increases the concentration of GABA in the synaptic cleft by 715 
inhibition of the GABA transporter 1, but without having significant affinity for 716 
any neurotransmitter receptor binding sites in the central nervous system 717 
(Suzdak and Jansen, 1995). Importantly, in rat hippocampal slice preparations, 718 
tiagabine had no effect on the amplitude of low- and high-intensity single-pulse 719 
evoked inhibitory post-synaptic potentials (Jackson, et al., 1999), in contrast to 720 
positive modulators at GABAA receptors, such as benzodiazepines (Thomson, 721 
et al., 2000). For this reason, TGB may have failed to modulate single-pulse 722 
TMS evoked neuronal activity in the human brain as measured by TEP 723 
amplitudes.  724 
 725 
In conclusion, the present study used three different drugs with specific modes 726 
of action to further elucidate the pharmaco-physiological characteristics of TMS-727 
evoked EEG potentials (TEPs), emergent non-invasive markers of excitability 728 
and effective connectivity of the human brain. We found that carbamazepine, a 729 
VGSC blocker depressed the P25 and P180 potentials, while brivaracetam that 730 
decreases neuronal excitability through binding to the presynaptic protein SV2A 731 
decreased the N100 potential in the non-stimulated hemisphere, and tiagabine, 732 
a GABA re-uptake inhibitor without direct modulating action on receptors in the 733 
central nervous system had no effect. Together with data from previous 734 
pharmaco-TMS-EEG studies the present findings corroborate the view that the 735 
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P25 represents axonal excitability of the corticospinal system, the N100 in the 736 
non-stimulated hemisphere propagated activity suppressed by positive 737 
modulation of GABAA receptors, and the P180 late activity particularly sensitive 738 
to VGSC blockade.  739 
 740 
Limitations 741 
Pharmaco-TMS-EEG is still a pioneering approach with many challenges, but 742 
we did our best to prevent potential confounds by running a double-blinded, 743 
randomized, placebo-controlled crossover design and state-of-the-art 744 
neuronavigated TMS-EEG procedures and analyses. Nonetheless, there are a 745 
few caveats to consider: While we controlled for multiple comparisons regarding 746 
the number of EEG channels and time points, the assessment of multiple 747 
different drugs inevitably comes at the risk of false positive findings, no matter 748 
whether within a single-study or across multiple studies and research groups. 749 
The only real solution to this issue is replication across labs, which we hereby 750 
explicitly encourage. In general, TEPs can be inherently confounded by auditory 751 
and somatosensory co-stimulation (Conde, et al., 2018; Gordon, et al., 2018; 752 
Herring, et al., 2015). While auditory noise masking can reduce its impact, and 753 
the post-pre and drug-placebo comparison remove most of these confounds, it 754 
is possible that a pharmacological modulation of residual auditory and 755 
somatosensory evoked potentials adds to the drug-induced changes in truly 756 
transcranial evoked brain responses. This potential confound has to be carefully 757 
assessed for each individual case, in particular for components that appear 758 
remotely to the stimulation site, such as the P180 as discussed in detail in the 759 
TMS-EEG section above. In general, remote TEP components are more difficult 760 
to interpret than those at the stimulation site, as they may have multiple origins. 761 
While they can indeed reflect multisensory co-activations, they may also result 762 
from actual signal propagation (also transcallosal) within the stimulated network 763 
(Ilmoniemi, et al., 1997; Massimini, et al., 2005), or from projections to the 764 
remote surface from dipoles located at deeper sources (Litvak, et al., 2007). In 765 
the future, realistic sham conditions and source localized TEP analyses may 766 
help to disentangle these contributions. However, TEP analyses in channel 767 
space are well established and, importantly, allow comparability with previously 768 
published studies.  769 
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Figures 1043 
 1044 
 1045 
Figure 1: Time line of an experimental session. 1046 
 1047 
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 1048 
Figure 2. Individual and mean changes (± SEM) in RMT and SI1mV (post-1049 
drug/pre-drug) in all drug conditions (CBZ, carbamazepine; TGB, tiagabine; 1050 
BRV, brivaracetam; and PBO, placebo). CBZ increased RMT compared to 1051 
baseline and placebo (p < 0.05) and both CBZ and BRV increased S1mV 1052 
compared to baseline (p < 0.05). Asterisks indicate significant comparisons with 1053 
p < 0.05, hashtags indicate non-significant comparisons with p < 0.1.  1054 
 1055 
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 1056 
Figure 3. Mean MEP input-output curves (shadings: ± 1 SEM) plotted against 1057 
seven different stimulus intensities before (black) and after (gray) intake of the 1058 
four drug conditions: carbamazepine (top left), tiagabine (top right), 1059 
brivaracetam (bottom left) and placebo (bottom right). The hashtag indicates a 1060 
non-significant (p < 0.1) drug-related change of the MEP curve. RMT, resting 1061 
motor threshold, as determined before drug intake.  1062 
 1063 
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 1064 
Figure 4. Mean SICI intensity curves (shadings: ± 1 SEM) plotted as a function 1065 
of the six conditioning stimulus (CS) intensities before (black) and after (gray) 1066 
intake of carbamazepine (top left), tiagabine (top right), brivaracetam (bottom 1067 
left), and placebo (bottom right). The asterisk indicates a significant (p < 0.05) 1068 
drug-related change of the SICI intensity curve. RMT, resting motor threshold; 1069 
cMEP, conditioned motor evoked potential amplitude; uMEP, unconditioned 1070 
motor evoked potential amplitude. 1071 
 1072 
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 1073 
Figure 5. TEPs before drug intake. TEPs (shadings: ± 1 SEM) were plotted for 1074 
channel Cz at baseline (pre-drug) in the four different drug conditions (CBZ, 1075 
carbamazepine; TGB, tiagabine; BRV, brivaracetam; and PBO, placebo) and 1076 
labeled based on their approximate latency (P25, N45, P70, N100, and P180) 1077 
relative to the time of the TMS pulse over the left M1 (time 0, vertical dashed 1078 
line). Topographical distributions of surface voltages illustrated in the bottom 1079 
were grand averaged over the four drug conditions in non-overlapping TOIs 1080 
after TMS (P25: 15–35 ms; N45: 36–50 ms; P70: 51– 85 ms; N100: 86–150 ms; 1081 
P180: 151 –280 ms). Note that voltage topographies may not reveal accurate 1082 
locations for low amplitude components (e.g., N45, P70) that peak during the 1083 
flanks of high amplitude components (e.g., N100).  1084 
 1085 
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 1086 
Figure 6. Carbamazepine-induced changes of TEPs. CBZ decreased the (A) 1087 
P25, (B) N100 and (C) P180 TEP components. TEPs (shadings: ± 1 SEM) 1088 
plotted for grand averages of those channels constituting a cluster of significant 1089 
differences versus baseline (post-CBZ – pre-CBZ), separately for pre-drug 1090 
(blue) and post-drug (red) measures. Horizontal black bars underneath the 1091 
TEPs denote the significant clusters in time (*p < 0.05, #p < 0.1). T-statistic 1092 
maps of the TEP amplitude plotted versus placebo (CBZ(post-pre) vs. 1093 
placebo(post-pre)). Channels constituting significant clusters of changes in this 1094 
interaction are indicated by asterisks in the t-statistic maps.  1095 
 1096 
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 1097 
Figure 7. Brivaracetam-induced changes of TEPs. BRV decreased the N100 1098 
potential in the non-stimulated right hemisphere. TEPs (shadings: ± 1 SEM) 1099 
plotted for grand averages of those channels that showed a significant 1100 
difference versus baseline (post-BRV – pre-BRV), separately for pre-drug (blue) 1101 
and post-drug (red) measures. Horizontal black bars underneath the TEPs 1102 
denote significant clusters in time (*p < 0.05). T-statistic maps of the TEP 1103 
amplitude plotted versus placebo (BRV(post-pre) vs. placebo(post-pre)). 1104 
Channels constituting significant clusters of changes in this interaction are 1105 
indicated by asterisks in the t-statistic maps.  1106 
 1107 
 1108 
 1109 
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 1110 
Figure 8. Individual and mean changes (± SEM) of drug-induced changes in 1111 
TEP component amplitudes, averaged across channels within each significant 1112 
(p < 0.05) cluster that was detected for (A) CBZ (cf. Figure 6) and BRV (cf. 1113 
Figure 7).   1114 
 1115 
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 1116 
Figure 9. Drug-induced changes in spontaneous oscillatory power. Grand 1117 
average power spectra (shadings: ± 1 SEM) are plotted for the pre-TMS EEG 1118 
period of pre-drug (blue) and post-drug (red) measures for carbamazepine 1119 
(CBZ, top left), tiagabine (TGB, top right), brivaracetam (BRV, bottom left), and 1120 
placebo (PBO, bottom right). CBZ mainly increased beta band power, while 1121 
TGB caused enormous power increases in all frequency bands (delta, theta, 1122 
alpha, and beta). TGB-induced changes in delta and beta bands were 1123 
particularly strong. There were no drug-induced power changes in other drug 1124 
conditions or for other frequency bands. Power spectra are plotted for channel 1125 
Cz, and asterisks indicate significant drug-related changes (p < 0.05). T-statistic 1126 
maps plotted versus placebo (drug(post-pre) vs. placebo(post-pre)), and 1127 
channels forming significant clusters are marked with asterisks in the t-statistic 1128 
maps. 1129 
 1130 
 
 
42 
Supplementary material 1131 
Table S1. Localization (significant electrodes) of carbamazepine effects on TEP 1132 
amplitudes 1133 
RMT 
adjusted 
vs. 
baseline 
P25 
over the left 
MC 
▼ # C3, Fz, Cz, C1, FC3 
P25 
over the right 
POC 
▼ * 
P4‚ O2‚ P8‚ Iz, CP6‚ TP10‚ 
Oz‚ O1, P7‚ Pz‚ TP9,  
P2‚ P6‚ PO8‚ Poz 
N100 
over the right 
MC 
▼ # C4, Fz, Cz, Pz, C1 
N100 
over the left 
POC 
▼ * 
P3‚ O1‚ O2‚ T7‚ P7‚ Iz‚ 
CP5‚ TP9‚ TP10‚ PO4‚ C5‚  
P5‚ TP7‚ PO7‚ POz‚ Oz 
P180 
over the right 
MC 
▼ * 
C3‚ C4‚ P3‚ P4‚ Cz‚ Pz‚ 
FC1‚ CP1‚ F1‚ C1‚ P2‚ 
FC3‚  
FCz 
vs. 
placebo 
P25 
over the left 
MC 
▼ * 
F3‚ C3‚ F7‚ Fz‚ Cz‚ FC1‚ 
CP1‚ FC5‚ CP5‚ F1‚ C1‚  
FC3 
P25 
over the right 
POC 
▼ * 
P4‚ O2‚ T8‚ P8‚ Iz‚ CP6‚ 
TP10‚ Oz‚ O1‚ TP9‚ P6‚  
PO8‚ POz‚ PO3‚ PO4‚ 
TP8‚ PO7 
N100 
over the right 
MC 
▼ # F4, FC2, CP2, FC6, F2 
N100 
over the left 
POC 
▼ # 
O2, Iz, TP10, C5, P5, 
TP7, Oz 
P180 
over the right 
MC 
▼ * 
C4, P4, Fz, Cz, FC2, CP2, 
CP6, F2, C1, FC3 
RMT 
unadjusted 
vs. 
baseline 
P25 
over the left 
MC 
▼ # 
F3‚ C3‚ F7‚ Fz‚ Cz‚ FC1‚ 
CP1‚ FC5‚ CP5‚ F1‚ C1‚  
FC3 
P25 
over the right 
POC 
▼ * 
P4‚ O2‚ P8‚ Iz, CP6‚ TP10‚ 
Oz‚ Pz‚ P2‚ P6‚ PO8‚  
POz 
N45 over the right 
MC 
▲ # 
P4, O2, P8, Iz, CP6, 
TP10, Oz 
N45 over the left ▲ # C3, CP5, C1, FC3 
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MC 
P180 
over the right 
MC 
▼ * 
C3‚ C4‚ P3‚ P4‚ Cz‚ Pz‚ 
FC1‚ CP1‚ F1‚ C1‚ P2‚ 
FC3‚  
FCz 
vs. 
placebo 
P25 
over the left 
MC 
▼ * 
F3‚ C3‚ FC1‚ CP1‚ FC5‚ 
CP5‚ F1, C1, FC3‚ Cz 
P25 
over the right 
POC 
▼ * 
C4‚ P4‚ O2‚ T8‚ P8‚ Iz‚ 
CP6‚ TP10‚ CP4‚ PO4‚ C6‚ 
P6‚ TP8‚ Oz 
N45 
over the left 
MC 
▲ * 
F3‚ C3, P3‚ FC1‚ FC5‚ 
CP5‚ C1‚ FC3 
N45 
over the right 
MC 
▲ * 
F4‚ C4‚ P4‚ O2‚ T8‚ P8‚ Iz‚ 
FC2‚ CP2‚ FC6‚ CP6‚  
TP10‚ F2‚ Fpz‚ Oz 
 P180 
over the right 
POC 
▼ * 
C4, P4, Fz, Cz, FC2, CP2, 
FC6, CP6, F2, C1 
 1134 
MC, Motor Cortex; POC, Parieto-Occipital Cortex; ▲, increase; ▼, decrease; #, p < 0.1; *, 1135 
p < 0.05. 1136 
  1137 
 
 
44 
Table S2. Localization (significant electrodes) of brivaracetam effects on TEP 1138 
amplitude 1139 
vs. 
baseline 
N100 over the right MC ▼ * 
F4‚ C4‚ Cz‚ FC2‚ CP2‚ FC6‚ CP6‚ F2, 
Fz 
 P180 over the right MC ▼ # 
C3‚ C4‚ P3‚ P4‚ Cz‚ Pz‚ FC1‚ CP1‚ F1‚ 
C1‚ P2‚ FC3‚ FCz 
vs. 
placebo 
N100 
over the right MC 
▼ * 
F4‚ C4‚ Cz‚ FC2‚ CP2‚ FC6‚ CP6‚ F2, 
Fz 
P180  - - - 
 1140 
MC, Motor Cortex; ▼, decrease; #, p < 0.1; *, p < 0.05  1141 
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 1142 
 1143 
Figure S1. Carbamazepine induced changes of TEPs. (A) TEPs recorded with 1144 
adjusted TMS intensity. (B) TEPs recorded without adjusted TMS intensity. CBZ 1145 
suppressed the P25 and P180 with and without adjusting TMS intensity. In 1146 
contrast, without adjustment, there was an increase in N45 potential, which was 1147 
no longer significant when adjusting TMS intensity. Moreover, there was a 1148 
significant decrease in the N100 potential only after adjusting the intensity for 1149 
CBZ-induced RMT increases. TEPs (shadings: ± 1 SEM) plotted as grand 1150 
averages of those channels constituting a significant cluster of differences 1151 
versus baseline (post-CBZ – pre-CBZ), separately for pre-drug (blue) and post-1152 
drug (red) measures. Horizontal black bars underneath the TEPs denote the 1153 
significant clusters in time (*p < 0.05, #p < 0.1). T-statistic maps of the TEP 1154 
amplitude were plotted versus placebo (CBZ(post-pre) vs. placebo(post-pre)) 1155 
and versus baseline (post-CBZ – pre-CBZ). Channels constituting a significant 1156 
cluster of changes vs. baseline or vs. placebo are marked by asterisks in the 1157 
corresponding t-statistic maps. 1158 
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 1159 
Figure S2.  Brivaracetam induced changes of TEPs. (A) BRV decreased the 1160 
N100 compared to both baseline and placebo contralateral to the stimulation 1161 
site. (B) There was also a trend-wise reduction in P180 potential only when 1162 
compared to baseline. TEPs (shadings: ± 1 SEM) plotted for grand averages of 1163 
those channels constituting a significant cluster of differences versus baseline 1164 
(post-BRV – pre-BRV), separately for pre-drug (blue) and post-drug (red). 1165 
Horizontal black bars underneath the TEPs denote significant clusters in time 1166 
(*p < 0.05, #p < 0.1). T-statistic maps of the TEP amplitude were plotted versus 1167 
placebo (BRV(post-pre) vs. placebo(post-pre)) and versus baseline (post-BRV – 1168 
pre-BRV). Channels constituting a significant cluster of changes vs. baseline or 1169 
vs. placebo are marked by asterisks in the corresponding t-statistic maps.  1170 
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 1171 
 1172 
Figure S3. Drug-induced changes of spontaneous oscillatory power. Grand 1173 
average power spectra (shadings: ± 1 SEM) are plotted for (A) the pre-TMS 1174 
period and (B) the eyes open resting state EEG recording for pre-drug (blue) 1175 
and post-drug (red) measures, separately for carbamazepine (CBZ), tiagabine 1176 
(TGB), brivaracetam (BRV), and placebo. CBZ increased the power of 1177 
spontaneous oscillations in the beta band during the pre-TMS period, and in 1178 
theta, alpha, and beta bands for the resting state EEG recording. TGB caused 1179 
particularly strong effects in all frequency bands (delta, theta, alpha and beta) in 1180 
both pre-TMS periods and resting state EEG recordings, that were most 1181 
pronounced in delta and theta bands. There were no drug-induced changes in 1182 
other drug conditions or other frequency bands. Power spectra are plotted for 1183 
channel Cz, and asterisks indicate significant drug related changes (p < 0.05). 1184 
T-statistic maps are plotted versus placebo (drug(post-pre) vs. placebo(post-1185 
pre)) and versus baseline (post-drug – pre-drug), and channels forming 1186 
significant clusters of increased power are marked with asterisks in the 1187 
corresponding t-statistic maps. 1188 
 1189 
 1190 
